Browse by Research Team

2024

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Rücker, F.G., Bullinger, L., Cocciardi, S., Skambraks, S., Luck, T.J., Weber, D., Krzykalla, J., Pozek, E., Schneider, I.J., Corbacioglu, A., Gaidzik, V.I., Meid, A., Aicher, S., Stegelmann, F., Schrade, A., Theis, F., Fiedler, W., Salih, H.R., Wulf, G.G., Salwender, H.J., Schroeder, T., Götze, K.S., Kühn, M.W.M., Lübbert, M., Schlenk, R.F., Benner, A., Thol, F.R., Heuser, M., Ganser, A., Döhner, H. and Döhner, K.
Blood Advances 8 (23): 6067-6080. 10 December 2024

Diagnosing recipient- vs. donor-derived posttransplant myelodysplastic neoplasm via targeted single-cell mutational profiling.
Ihlow, J., Penter, L., Vuong, L.G., Bischoff, P., Obermayer, B., Trinks, A., Blau, O., Behnke, A., Conrad, T., Morkel, M., Wu, C.J., Westermann, J., Bullinger, L., von Brünneck, A.C., Blüthgen, N., Horst, D. and Praktiknjo, S.D.
Med 6 December 2024 (In Press)

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology.
Krüger, J., Blau, I.W., Blau, O., Bettelli, A., Rocchi, L., Bocchi, M., Krönke, J., Bullinger, L., Keller, U. and Nogai, A.
Leukemia Research 147 : 107599. December 2024

Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype.
Leppä, A.M., Grimes, K., Jeong, H., Huang, F.Y., Andrades, A., Waclawiczek, A., Boch, T., Jauch, A., Renders, S., Stelmach, P., Müller-Tidow, C., Karpova, D., Sohn, M., Grünschläger, F., Hasenfeld, P., Benito Garagorri, E., Thiel, V., Dolnik, A., Rodriguez-Martin, B., Bullinger, L., Mrózek, K., Eisfeld, A.K., Krämer, A., Sanders, A.D., Korbel, J.O. and Trumpp, A.
Nature Genetics 56 (12): 2790-2803. December 2024

New cardiovascular biomarkers in patients with advanced cancer – a prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNP.
Anker, M.S., Lück, L.C., Khan, M.S., Porthun, J., Hadzibegovic, S., Lena, A., Wilkenshoff, U., Weinländer, P., Evertz, R., Totzeck, M., Mahabadi, A.A., Rassaf, T., Anker, S.D., Bullinger, L., Keller, U., Karakas, M., Landmesser, U., Butler, J. and von Haehling, S.
European Journal of Heart Failure 26 November 2024 (In Press)

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project.
Voso, M.T., Guarnera, L., Lehmann, S., Döhner, K., Döhner, H., Platzbecker, U., Russell, N.H., Dillon, R.J., Thomas, I., Ossenkoppele, G.J., Haferlach, T., Vignetti, M., La Sala, E., Piciocchi, A., Fazi, P., Villaverde Ramiro, Á., Tur Giménez, L., Gurnari, C., Bullinger, L. and Hernandez, J.M.
Blood 8 November 2024 (In Press)

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Sobas, M.A., Turki, A.T., Ramiro, A.V., Sánchez, A.H., Elicegui, J.M., González, T., Melchor, R.A., Abáigar, M., Tur, L., Dall'Olio, D., Sträng, E., Tettero, J.M., Castellani, G., Benner, A., Döhner, K., Thiede, C., Metzeler, K.H., Haferlach, T., Damm, F., Ayala, R., Martínez-López, J., Mills, K.I., Sierra, J., Lehmann, S., Porta, M.G.D., Mayer, J., Reinhardt, D., Medina, R.V., Schulze-Rath, R., Barbus, M., Hernández-Rivas, J.M., Huntly, B.J.P., Ossenkoppele, G., Döhner, H. and Bullinger, L.
Haematologica 7 November 2024 (In Press)

Review of preclinical data on hyperthermia treatment in lymphomas and its potential for clinical application.
Scharr, M.V., Damm, F., Krahl, P., Dieper, A., Veltsista, P.D., Hansch, A., Beck, M., Gerster, D., Giovannelli, A.C., Bullinger, L., Zips, D. and Ghadjar, P.
International Journal of Hyperthermia 41 (1): 2418427. 3 November 2024

Tracking rare single donor and recipient immune and leukemia cells after allogeneic hematopoietic cell transplantation using mitochondrial DNA mutations.
Penter, L., Cieri, N., Maurer, K., Kwok, M., Lyu, H., Lu, W.S., Oliveira, G., Gohil, S.H., Leshchiner, I., Lareau, C.A., Ludwig, L.S., Neuberg, D.S., Kim, H.T., Li, S., Bullinger, L., Ritz, J., Getz, G., Garcia, J.S., Soiffer, R.J., Livak, K.J. and Wu, C.J.
Blood Cancer Discovery 5 (6): 442-459. 1 November 2024

Acute myeloid leukemia: does sex matter?
Tettero, J.M., Cloos, J. and Bullinger, L.
Leukemia 38 (11): 2329-2331. November 2024

Increased abundance of Firmicutes and depletion of Bacteroidota predicts poor outcome in chronic lymphocytic leukemia.
Paziewska, M., Szelest, Mo., Kiełbus, M., Masternak, M., Zaleska, J., Wawrzyniak, E., Kotkowska, A., Siemieniuk-Ryś, M., Morawska, M., Kalicińska, E., Jabłonowska, P., Wróbel, T., Wolska-Washer, A., Błoński, J.Z., Robak, T., Bullinger, L. and Giannopoulos, K.
Oncology letters 28 (5): 552. November 2024

Therapy adherence after interdisciplinary tumour board discussion is associated with improved outcome in soft tissue sarcoma: a Charité Comprehensive Cancer Centre analysis.
Strönisch, A., Rau, D., Wittenberg, S., Kaul, D., Koulaxouzidis, G., Öllinger, R., von Laffert, M., Jarosch, A., Schäfer, F., Keilholz, U., Bullinger, L., Märdian, S., Striefler, J. and Flörcken, A.
International Journal of Cancer 16 October 2024 (In Press)

Altered enhancer-promoter interaction leads to MNX1 expression in pediatric acute myeloid leukemia with t(7;12)(q36;p13).
Weichenhan, D., Riedel, A., Sollier, E., Toprak, U.H., Hey, J., Breuer, K.H., Wierzbinska, J.A., Touzart, A., Lutsik, P., Bähr, M., Östlund, A., Nilsson, T., Jacobsson, S., Waraky, A., Behrens, Y.L., Göhring, G., Schlegelberger, B., Steinek, C., Harz, H., Leonhardt, H., Dolnik, A., Reinhardt, D., Bullinger, L., Palmqvist, L., Lipka, D.B. and Plass, C.
Blood Advances 8 (19): 5100-5111. 8 October 2024

Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders.
Mougiakakos, D., Sengupta, R., Gold, R., Schroers, R., Haghikia, A., Lorente, M., Pendleton, M., Register, A., Heesen, C., Kröger, N., Schett, G., Mackensen, A., Podoll, A., Gutman, J., Furie, R., Bayer, R., Distler, J.H.W., Dietrich, S., Krönke, G., Bullinger, L. and Walker, K.
Cytotherapy 5 October 2024 (In Press)

A high proportion of germline variants in pediatric chronic myeloid leukemia.
Krumbholz, M., Dolnik, A., Sträng, E., Ghete, T., Skambraks, S., Hutter, S., Simonis, A., Stegelmann, F., Suttorp, M., Horn, A.H.C., Sticht, H., Haferlach, T., Bullinger, L. and Metzler, M.
Molecular Cancer 23 (1): 206. 26 September 2024

Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy.
Gross, S., Ihlow, J., Busack, L., Adamiak, K., Schrezenmeier, J., Jesse, J., Schwarz, M., Flörcken, A., Vuong, L.G., Rieger, K., Krönke, J., le Coutre, P., Boldt, V., von Brünneck, A.C., Horst, D., Burmeister, T., Blau, I.W., Keller, U., Bullinger, L. and Westermann, J.
Blood Cancer Journal 14 (1): 160. 16 September 2024

Pyjacker identifies enhancer hijacking events in acute myeloid leukemia including MNX1 activation via deletion 7q.
Sollier, E., Riedel, A., Toprak, U.H., Wierzbinska, J.A., Weichenhan, D., Schmid, J.P., Hakobyan, M., Touzart, A., Jahn, E., Vick, B., Brown-Burke, F., Kelly, K., Kelekci, S., Pejkovska, A., Goyal, A., Baehr, M., Breuer, K., Chen, M.J.M., Llamazares-Prada, M., Hartmann, M., Schoenung, M., Correia, N., Trumpp, A., Abdullah, Y., Klingmueller, U., Mughal, S.S., Brors, B., Westermann, F., Schlesner, M., Vosberg, S., Herold, T., Greif, P.A., Pfeifer, D., Luebbert, M., Fischer, T., Heidel, F., Gebhard, C., Walter, W., Haferlach, T., Eisfeld, A.K., Mrozek, K., Nicolet, D., Bullinger, L., Smeenk, L., Erpelinck, C., Mulet-Lazaro, R., Delwel, R., Ernst, A., Scherer, M., Lutsik, P., Jeremias, I., Doehner, K., Doehner, H., Lipka, D.B. and Plass, C.
bioRxiv : 2024.09.11.611224. 13 September 2024

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernández-Sánchez, A., González, T., Sobas, M., Sträng, E., Castellani, G., Abáigar, M., Valk, P.J.M., Villaverde Ramiro, Á., Benner, A., Metzeler, K.H., Azibeiro, R., Tettero, J.M., Martínez-López, J., Pratcorona, M., Martínez Elicegui, J., Mills, K.I., Thiede, C., Sanz, G., Döhner, K., Heuser, M., Haferlach, T., Turki, A.T., Reinhardt, D., Schulze-Rath, R., Barbus, M., Hernández-Rivas, J.M., Huntly, B., Ossenkoppele, G., Döhner, H. and Bullinger, L.
Leukemia 38 (9): 1929-1937. September 2024

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik, A., Tilgner, M., Silva, P., Estrada, N., Altwasser, R., Jahn, E., Heuser, M., Hou, H.A., Pratcorona, M., Hills, R.K., Metzeler, K.H., Fenwarth, L., Dolnik, A., Terre, C., Kopp, K., Blau, O., Szyska, M., Christen, F., Krönke, J., Vasseur, L., Löwenberg, B., Esteve, J., Valk, P.J.M., Duchmann, M., Chou, W.C., Linch, D.C., Döhner, H., Gale, R.E., Döhner, K., Bullinger, L., Yoshida, K. and Damm, F.
Journal of Hematology & Oncology 17 (1): 70. 19 August 2024

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.
Ramberger, E., Sapozhnikova, V., Ng, Y.L.D., Dolnik, A., Ziehm, M., Popp, O., Sträng, E., Kull, M., Grünschläger, F., Krüger, J., Benary, M., Müller, S., Gao, X., Murgai, A., Haji, M., Schmidt, A., Lutz, R., Nogai, A., Braune, J., Laue, D., Langer, C., Khandanpour, C., Bassermann, F., Döhner, H., Engelhardt, M., Straka, C., Hundemer, M., Beule, D., Haas, S., Keller, U., Einsele, H., Bullinger, L., Knop, S., Mertins, P. and Krönke, J.
Nature Cancer 5 (8): 1267-1284. August 2024

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).
Rücker, F.G., Corbacioglu, A., Krzykalla, J., Cocciardi, S., Lengerke, C., Germing, U., Wulf, G., Samra, M.A., Teichmann, L.L., Lübbert, M., Kühn, M.W.M., Bentz, M., Westermann, J., Bullinger, L., Gaidzik, V.I., Meid, A., Aicher, S., Stegelmann, F., Weber, D., Schrade, A., Thol, F., Heuser, M., Ganser, A., Benner, A., Döhner, H. and Döhner, K.
HemaSphere 8 (7): e123. July 2024

Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment.
Dörr, A., Vogel, I., Wittenbecher, F., Westermann, J., Thuss-Patience, P., Ahn, J., Pelzer, U., Hardt, J., Bullinger, L. and Flörcken, A.
Palliative Care and Social Practice 18 : 26323524241260424. 24 June 2024

Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends, C.M., Kopp, K., Hablesreiter, R., Estrada, N., Christen, F., Moll, U.M., Zeillinger, R., Schmitt, W.D., Sehouli, J., Kulbe, H., Fleischmann, M., Ray-Coquard, I., Zeimet, A., Raspagliesi, F., Zamagni, C., Vergote, I., Lorusso, D., Concin, N., Bullinger, L., Braicu, E.I. and Damm, F.
Leukemia 38 (6): 1378-1389. June 2024

Oligonucleotide library screening for identification of virus-specific T-cell receptors.
Welters, M.L., Stadler, S., Anastasopoulou, V., Bullinger, L., Leisegang, M., Kammertöns, T., Welters, C. and Hansmann, L.
European Journal of Immunology 56 (6): e2350908. June 2024

Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Oerlemans, S., De Rooij, B.H., Bennink, C., Bullinger, L., Broijl, A., D'Agostino, M., Laane, E., Lupo-Stanghellini, M.T., Perrot, A., Wester, R., Cursaru, V., Scheurer, H., Vesseur, J., Dalal, M., Sen, R., Stamm, T., Ludwig, H. and Sonneveld, P.
Haematologica 109 (6): 1956-1959. June 2024

Thrombus or tumor? A case report of a rare sarcoma entity: intimal sarcoma of the pulmonary arteries.
Dörr, A., Flörcken, A, Bullinger, L., Capper, D., Von Deimling, A., Kaul, D., Märdian, S., Starck, C., Horst, D., Dragomir, M.P., Schäfer, F.M. and Jarosch, A.
Molecular Biology Reports 51 : 568. 24 April 2024

Making AML fly too close to the sun.
Bullinger, L. and Krönke, J.
Blood 143 (15): 1438-1439. 11 April 2024

Association of an impaired GH‑IGF‑I axis with cardiac wasting in patients with advanced cancer.
Fröhlich, A.K., Porthun, J., Talha, K.M., Lena, A., Hadzibegovic, S., Wilkenshoff, U., Sonntag, F., Nikolski, A., Ramer, L.V., Zeller, T., Keller, U., Bullinger, L., Anker, S.D., Haverkamp, W., von Haehling, S., Doehner, W., Rauch, U., Skurk, C., Cleland, J.G.F., Butler, J., Coats, A.J.S., Landmesser, U., Karakas, M. and Anker, M.S.
Clinical Research in Cardiology 8 April 2024 (In Press)

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry.
Ben Hamza, A., Welters, C., Stadler, S., Brüggemann, M., Dietze, K., Brauns, O., Brümmendorf, T.H., Winkler, T.H., Bullinger, L., Blankenstein, T., Rosenberger, L., Leisegang, M., Kammertöns, T., Herr, W., Moosmann, A., Strobel, J., Hackstein, H., Dornmair, K., Beier, F. and Hansmann, L.
Blood 143 (14): 1365-1378. 4 April 2024

HLA-C*04:09N is expressed at the cell surface and triggers peptide-specific T-cell activation.
Welters, C., Welters, M.L., Stadler, S., Bullinger, L., Strobel, J., Hackstein, H., Dhamodaran, A., Blankenstein, T. and Hansmann, L.
Haematologica 109 (4): 1121-1127. April 2024

Comparable CD8(+) T-cell responses to SARS-CoV-2 vaccination in single-cell transcriptomics of recently allogeneic transplanted patients and healthy individuals.
Tranter, Eva, Frentsch, Marco, Hütter-Krönke, Marie Luise, Vuong, Giang Lam, Busch, David, Loyal, Lucie, Henze, Larissa, Rosnev, Stanislav, Blau, Igor-Wolfgang, Thiel, Andreas, Beule, D., Bullinger, L., Obermayer, B. and Na, I.K.
Journal of Medical Virology 96 (3): e29539. March 2024

Covering hierarchical dirichlet mixture models on binary data to enhance genomic stratifications in onco-hematology.
Dall'Olio, D., Sträng, E., Turki, A.T., Tettero, J.M., Barbus, M., Schulze-Rath, R., Elicegui, J.M., Matteuzzi, T., Merlotti, A., Carota, L., Sala, C., Della Porta, M.G., Giampieri, E., Hernández-Rivas, J.M., Bullinger, L. and Castellani, G.
PLoS Computational Biology 20 (2): e1011299. 2 February 2024

Genetic characterization of primary mediastinal B-cell lymphoma: pathogenesis and patient outcomes.
Noerenberg, D., Briest, F., Hennch, C., Yoshida, K., Hablesreiter, R., Takeuchi, Y., Ueno, H., Staiger, A.M., Ziepert, M., Asmar, F., Locher, B.N., Toth, E., Weber, T., Amini, R.M., Klapper, W., Bouzani, M., Poeschel, V., Rosenwald, A., Held, G., Campo, E., Ishaque, N., Stamatopoulos, K., Kanellis, G., Anagnostopoulos, I., Bullinger, L., Goldschmidt, N., Zinzani, P.L., Bödör, C., Rosenquist, R., Vassilakopoulos, T.P., Ott, G., Ogawa, S. and Damm, F.
Journal of Clinical Oncology 42 (4): 452-466. 1 February 2024

Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.
Bruedigam, C., Porter, A.H., Song, A., Vroeg In de Wei, G., Stoll, T., Straube, J., Cooper, L., Cheng, G., Kahl, V.F.S., Sobinoff, A.P., Ling, V.Y., Jebaraj, B.M.C., Janardhanan, Y., Haldar, R., Bray, L.J., Bullinger, L., Heidel, F.H., Kennedy, G.A., Hill, M.M., Pickett, H.A., Abdel-Wahab, O., Hartel, G. and Lane, S.W.
Nature Cancer 5 (1): 47-65. January 2024

2023

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology.
Klever, M.K., Sträng, E., Hetzel, S., Jungnitsch, J., Dolnik, A., Schöpflin, R., Schrezenmeier, J.F.F., Schick, F., Blau, O., Westermann, J., Rücker, F.G., Xia, Z., Döhner, K., Schrezenmeier, H., Spielmann, M., Meissner, A., Melo, U.S., Mundlos, S. and Bullinger, L.
Blood Advances 7 (21): 6520-6531. 14 November 2023

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Jahn, E., Saadati, M., Fenaux, P., Gobbi, M., Roboz, G.J., Bullinger, L., Lutsik, P., Riedel, A., Plass, C., Jahn, N., Walter, C., Holzmann, K., Hao, Y., Naim, S., Schreck, N., Krzykalla, J., Benner, A., Keer, H.N., Azab, M., Döhner, K. and Döhner, H.
Leukemia 37 (11): 2187-2196. November 2023

Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.
Briest, F., Noerenberg, D., Hennch, C., Yoshida, K., Hablesreiter, R., Nimo, J., Sasca, D., Kirchner, M., Mansouri, L., Inoue, Y., Wiegand, L., Staiger, A.M., Casadei, B., Korkolopoulou, P., Weiner, J., Lopez-Guillermo, A., Warth, A., Schneider, T., Nagy, Á., Klapper, W., Hummel, M., Kanellis, G., Anagnostopoulos, I., Mertins, P., Bullinger, L., Rosenquist, R., Vassilakopoulos, T.P., Ott, G., Ogawa, S. and Damm, F.
Leukemia 37 (11): 2237-2249. November 2023

Recent advances in precision medicine for acute myeloid leukemia.
Hernández-Sánchez, A. and Bullinger, L.
Current Opinion in Oncology 35 (6): 581-588. November 2023

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen.
Schmutz, M., Zucknick, M., Schlenk, R.F., Mertens, D., Benner, A., Weichenhan, D., Mücke, O., Döhner, K., Plass, C., Bullinger, L. and Claus, R.
Clinical Epigenetics 15 (1): 171. 26 October 2023

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.
Eifert, T., Hsu, C.J., Becker, A.L., Graessle, S., Horne, A., Bemmann, F., Zhang, Q., Heuser, M., Vasioukhin, V., Scholl, S., Hochhaus, A., Siegerist, F., Endlich, N., Bullinger, L., Lane, S.W., Haas, S., Schnoeder, T.M and Heidel, F.H.
Leukemia 37 (10): 2027-2035. October 2023

Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients.
Panagiota, V., Kerschbaum, J.F., Penack, O., Stein, C.M., Arends, C.M., Koenecke, C., Strzelecka, P.M., Kloos, A., Wiegand, L., Lasch, A., Altwasser, R., Halik, A., Gabdoulline, R., Thomson, J., Weibl, K., Franke, G.N., Berger, C., Hasenkamp, J., Ayuk, F., Na, I.K., Beutel, G., Keller, U., Bullinger, L., Wulf, G.G., Kröger, N., Vucinic, V., Heuser, M. and Damm, F.
HemaSphere 7 (10): e957. October 2023

The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of an inverted 55 base pair ABL1 intron 1b sequence: a detailed molecular analysis.
Burmeister, T., Bullinger, L. and le Coutre, P.
Acta Haematologica 146 (5): 413-418. October 2023

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski, K., Perez, A., Iacoboni, G., Blumenberg, V., Bücklein, V.L., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., Karschnia, P., Petrera, A., Reid, K., Faramand, R., Davila, M.L., Modi, K., Dean, E.A., Bachmeier, C., von Bergwelt-Baildon, M., Locke, F.L., Bethge, W., Bullinger, L., Mackensen, A., Barba, P., Jain, M.D. and Subklewe, M.
Science Advances 9 (38): eadg3919. 22 September 2023

Mechanisms of resistance to small molecules in acute myeloid leukemia.
Lang, T.J.L., Damm, F., Bullinger, L. and Frick, M.
Cancers 15 (18): 4573. 15 September 2023

Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker, M.S., Potthoff, S.K., Lena, A., Porthun, J., Hadzibegovic, S., Evertz, R., Denecke, C., Fröhlich, A.K., Sonntag, F., Regitz-Zagrosek, V., Rosen, S.D., Lyon, A.R., Lüscher, T.F., Spertus, J.A., Anker, S.D., Karakas, M., Bullinger, L., Keller, U., Landmesser, U., Butler, J. and von Haehling, S.
European Journal of Heart Failure 25 (9): 1635-1647. September 2023

Hand grip strength in patients with advanced cancer: a prospective study.
Hadzibegovic, S., Porthun, J., Lena, A., Weinlaänder, P., Lück, L.C., Potthoff, S.K., Rösnick, L., Fröhlich, A.K., Ramer, L.V., Sonntag, F., Wilkenshoff, U., Ahn, J., Keller, U., Bullinger, L., Mahabadi, A.A., Totzeck, M., Rassaf, T., von Haehling, S., Coats, A.J.S., Anker, S.D., Roeland, E.J., Landmesser, U. and Anker, M.S.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1682-1694. August 2023

Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma: association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use.
Bücklein, V., Perez, A., Rejeski, K., Iacoboni, G., Jurinovic, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Mhaskar, R., Wood, A., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., von Bergwelt, M., Barba, P., Subklewe, M. and Jain, M.D.
HemaSphere 7 (8): e907. August 2023

Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer.
Anker, M.S., Lena, A., Roeland, E.J., Porthun, J., Schmitz, S., Hadzibegovic, S., Sikorski, P., Wilkenshoff, U., Fröhlich, A.K., Ramer, L.V., Rose, M., Eucker, J., Rassaf, T., Totzeck, M., Lehmann, L.H., von Haehling, S., Coats, A.J.S., Friede, T., Butler, J., Anker, S.D., Riess, H., Landmesser, U., Bullinger, L., Keller, U. and Ahn, J.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1670-1681. August 2023

Personalizing precision medicine: Patients with AML perceptions about treatment decisions.
Grauman, A., Kontro, M., Haller, K., Nier, S., Aakko, S., Lang, K., Zingaretti, C., Meggiolaro, E., De Padova, S., Marconi, G., Martinelli, G., Heckman, C.A., Simonetti, G., Bullinger, L. and Kihlbom, U.
Patient Education and Counseling 115 : 107883. 5 July 2023

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Kühn, M.W.M., Schroeder, T., Mayer, K., Lübbert, M., Wattad, M., Götze, K., Fransecky, L., Koller, E., Wulf, G., Schleicher, J., Ringhoffer, M., Greil, R., Hertenstein, B., Krauter, J., Martens, U.M., Nachbaur, D., Samra, M.A., Machherndl-Spandl, S., Basara, N., Leis, C., Schrade, A., Kapp-Schwoerer, S., Cocciardi, S., Bullinger, L., Thol, F., Heuser, M., Paschka, P., Gaidzik, V.I., Saadati, M., Benner, A., Schlenk, R.F., Döhner, K. and Ganser, A.
Lancet Haematology 10 (7): e495-e509. July 2023

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke, M.L., Neagoie, A., Blau, I.W., Wais, V., Vuong, L., Gantner, A., Ahn, J., Penack, O., Schnell, J., Nogai, K.A., Eberspächer, B., Saadati, M., Benner, A., Bullinger, L., Döhner, H., Bunjes, D. and Sala, E.
Frontiers in Immunology 14 : 1174289. 3 May 2023

Clinical and prognostic relevance of cardiac wasting in patients with advanced cancer.
Lena, A., Wilkenshoff, U., Hadzibegovic, S., Porthun, J., Rösnick, L., Fröhlich, A.K., Zeller, T., Karakas, M., Keller, U., Ahn, J., Bullinger, L., Riess, H., Rosen, S.D., Lyon, A.R., Lüscher, T.F., Totzeck, M., Rassaf, T., Burkhoff, D., Mehra, M.R., Bax, J.J., Butler, J., Edelmann, F., Haverkamp, W., Anker, S.D., Packer, M., Coats, A.J.S., von Haehling, S., Landmesser, U. and Anker, M.S.
Journal of the American College of Cardiology 81 (16): 1569-1586. 25 April 2023

Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia.
Straube, J., Eifert, T., Vu, T., Janardhanan, Y., Haldar, R., von Eyss, B., Cooper, L., Bruedigam, C., Ling, V.Y., Cooper, E., Patch, A.M., Bullinger, L., Schnoeder, T.M., Bywater, M., Heidel, F.H. and Lane, S.W.
Leukemia 37 (4): 741-750. April 2023

Retained functional normal and preleukemic HSCs at diagnosis are associated to good prognosis in DNMT3Amut NPM1mut AMLs.
Donato, E., Correia, N.C., Andresen, C., Karpova, D., Würth, R., Klein, C., Sohn, M., Przybylla, A., Zeisberger, P., Rothfelder, K., Salih, H.R., Bonig, H., Stasik, S., Röllig, C., Dolnik, A., Bullinger, L., Buchholz, F., Thiede, C.D., Hübschmann, D. and Trumpp, A.
Blood Advances 7 (6): 1011-1018. 28 March 2023

Sarcoma patients admitted to the intensive care unit (ICU): predictive relevance of common sepsis and performance parameters.
Striefler, J.K., Binder, P.T., Brandes, F., Rau, D., Wittenberg, S., Kaul, D., Roohani, S., Jarosch, A., Schäfer, F.M., Öllinger, R., Märdian, S., Bullinger, L., Eckardt, K.U., Kruse, J. and Flörcken, A.
Cancer Management and Research 15 : 321-334. 27 March 2023

Associations of clonal hematopoiesis with recurrent vascular events and death in patients with incident ischemic stroke.
Arends, C.M., Liman, T.G., Strzelecka, P.M., Kufner, A., Löwe, P., Huo, S., Stein, C.M., Piper, S.K., Tilgner, M., Sperber, P.S., Dimitriou, S., Heuschmann, P., Hablesreiter, R., Harms, C., Bullinger, L., Weber, J.E., Endres, M. and Damm, F.
Blood 141 (7): 787-799. 16 February 2023

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
Zaleska, J., Kwasnik, P., Paziewska, M., Purkot, Jo., Szabelak, A., Jurek, M., Masny, N., Dziatkiewicz, I., Pronobis-Szczylik, B., Piebiak, A., Szymczyk, A., Jarosz-Chudzik, K., Bolkun, L., Kozlowska, K., Piszcz, J., Subocz, E., Halka, J., Bator, M., Kalicinska, E., Wrobel, T., Usnarska-Zubkiewicz, L., Rybka, J., Deren-Wagemann, I., Szyca-Smieszniak, M., Dybko, J., Hus, I., Pula, B., Cichocka, E., Rymko, M., Zdunczyk, D., Ziarkiewicz, M., Basak, G.W., Bullinger, L. and Giannopoulos, K.
International Journal of Cancer 15 (4): 705-712. 15 February 2023

Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation.
Obermayer, B., Keilholz, L., Conrad, T., Frentsch, M., Blau, I.W., Vuong, L., Lesch, S., Movasshagi, K., Tietze-Stolley, C., Loyal, L., Henze, L., Penack, O., Stervbo, U., Babel, N., Haas, S., Beule, D., Bullinger, L., Wittenbecher, F. and Na, I.K.
Frontiers in Immunology 14 : 1114368. 10 February 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri, L., Thorvaldsdottir, B., Sutton, L.A., Karakatsoulis, G., Meggendorfer, M., Parker, H., Nadeu, F., Brieghel, C., Laidou, S., Moia, R., Rossi, D., Catherwood, M., Kotaskova, J., Delgado, J., Rodríguez-Vicente, A.E., Benito, R., Rigolin, G.M., Bonfiglio, S., Scarfo, L., Mattsson, M., Davis, Z., Gogia, A., Rani, L., Baliakas, P., Foroughi-Asl, H., Jylhä, C., Skaftason, A., Rapado, I., Miras, F., Martinez-Lopez, J., de la Serna, J., Rivas, J.M.H., Thornton, P., Larráyoz, M.J., Calasanz, M.J., Fésüs, V., Mátrai, Z., Bödör, C., Smedby, K.E., Espinet, B., Puiggros, A., Gupta, R., Bullinger, L., Bosch, F., Tazón-Vega, B., Baran-Marszak, F., Oscier, D., Nguyen-Khac, F., Zenz, T., Terol, M.J., Cuneo, A., Hernández-Sánchez, M., Pospisilova, S., Mills, K., Gaidano, G., Niemann, C.U., Campo, E., Strefford, J.C., Ghia, P., Stamatopoulos, K. and Rosenquist, R.
Leukemia 37 (2): 339-347. February 2023

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen, A., Ben Hamza, A., Welters, C., Dietze, K., Bullinger, L., Rahn, H.P., Hartmann, S., Hansmann, M.L. and Hansmann, L.
Cancer Immunology Immunotherapy 72 (2): 515-521. February 2023

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
Denkinger, C.M., Janssen, M., Schäkel, U., Gall, J., Leo, A., Stelmach, P., Weber, S.F., Krisam, J., Baumann, L., Stermann, J., Merle, U., Weigand, M.A., Nusshag, C., Bullinger, L., Schrezenmeier, J.F., Bornhäuser, M., Alakel, N., Witzke, O., Wolf, T., Vehreschild, M.J.G.T., Schmiedel, S., Addo, M.M., Herth, F., Kreuter, M., Tepasse, P.R., Hertenstein, B., Hänel, M., Morgner, A., Kiehl, M., Hopfer, O., Wattad, M.A., Schimanski, C.C., Celik, C., Pohle, T., Ruhe, M., Kern, W.V., Schmitt, A., Lorenz, H.M., Souto-Carneiro, M., Gaeddert, M., Halama, N., Meuer, S., Kräusslich, H.G., Müller, B., Schnitzler, P., Parthé, S., Bartenschlager, R., Gronkowski, M., Klemmer, J., Schmitt, M., Dreger, P., Kriegsmann, K., Schlenk, Ri.F. and Müller-Tidow, C.
Nature Cancer 4 (1): 96-107. January 2023

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Weller, J., Schäfer, N., Schaub, C., Tzaridis, T., Zeyen, T., Schneider, M., Potthoff, A.L., Giordano, F.A., Steinbach, J.P., Zeiner, P.S., Kowalski, T., Sabel, M., Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Tabatabai, G., Ringel, F., Schmidt-Graf, F., Brehmer, S., Tonn, J.C., Bullinger, L., Vajkoczy, P., Glas, M., Vatter, H., Herrlinger, U. and Seidel, C.
Journal of Neuro-Oncology 161 (1): 147-153. January 2023

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
Ling, V.Y., Straube, J., Godfrey, W., Haldar, R., Janardhanan, Y., Cooper, L., Bruedigam, C., Cooper, E., Tavakoli Shirazi, P., Jacquelin, S., Tey, S.K., Baell, J., Huang, F., Jin, J., Zhao, Y., Bullinger, L., Bywater, M.J. and Lane, S.W.
Leukemia 37 (1): 143-153. January 2023

2022

Relapse of NPM1-mutated AML with extramedullary manifestation 17 years after allogeneic hematopoietic stem cell transplantation.
Braune, J., Rieger, K., Blau, O., Keller, U., Bullinger, L. and Krönke, J.
Case Reports in Hematology 2022 : 3317936. 28 December 2022

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck, F., Fischer, B., Witt, M., Muschhammer, J., Oelrich, J., da Costa Avelar, P.H., Tsoka, S., Bullinger, L., Seubert, E., Smit, D.J., Bokemeyer, C., Ackermann, C., Wellbrock, J., Haag, F. and Fiedler, W.
Journal for ImmunoTherapy of Cancer 10 (12): e004794. 22 December 2022

Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma.
Welters, C., Lammoglia Cobo, M.F., Stein, C.A., Hsu, M.T., Ben Hamza, A., Penter, L., Chen, X., Buccitelli, C., Popp, O., Mertins, P., Dietze, K., Bullinger, L., Moosmann, A., Blanc, E., Beule, D., Gerbitz, A., Strobel, J., Hackstein, H., Rahn, H.P., Dornmair, K., Blankenstein, T. and Hansmann, L.
Cancer Immunology Research 10 (11): 1407-1419. 1 November 2022

Widely applicable, extended flow cytometric stem cell enumeration panel for quality control of advanced cellular products.
Haussmann, K., Streitz, M., Takvorian, A., Grund, J., Skenderi, Z., Tietze-Bürger, C., Movassaghi, K., Künkele, A., Blum, A. and Bullinger, L.
Scientific Reports 12 (1): 17995. 26 October 2022

Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in hematologY added value framework for hematologic malignancies: a comparative analysis of existing tools.
Cerisoli, F., Ali, F., Bereczky, T., Bolaños, N., Bullinger, L., Dhanasiri, S., Gallagher, J., Pérez, S.G., Geissler, J., Guillevic, Y., Harrison, K., Naoum, A., Portulano, C., Rodríguez Vicente, A.E., Schulze-Rath, R., Gómez, G.Y., Sanz, G. and Hernández Rivas, J.M.
Value in Health 25 (10): 1760-1767. October 2022

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner, H., Weber, D., Krzykalla, J., Fiedler, W., Wulf, G.G., Salih, H.R., Lübbert, M., Kühn, M., Schroeder, T., Salwender, H., Götze, K.S., Westermann, J., Fransecky, L., Mayer, K., Hertenstein, B., Ringhoffer, M., Tischler, H.J., Machherndl-Spandl, S., Schrade, A., Paschka, P., Gaidzik, V.I., Theis, F., Thol, F.R., Heuser, M., Schlenk, R.F., Bullinger, L., Saadati, M., Benner, A., Larson, R.A., Stone, R.M., Döhner, K. and Ganser, A.
Blood Advances 6 (18): 5345-5355. 27 September 2022

Comorbidities rather than older age define outcome in adult patients with tumors of the Ewing sarcoma family.
Striefler, J.K., Schmiester, M., Brandes, F., Dörr, A., Pahl, S., Kaul, D., Rau, D., Dobrindt, E.M., Koulaxouzidis, G., Bullinger, L., Märdian, S. and Flörcken, A.
Cancer Medicine 11 (17): 3213-3225. September 2022

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn, N., Jahn, E., Saadati, M., Bullinger, L., Larson, R.A., Ottone, T., Amadori, S., Prior, T.W., Brandwein, J.M., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Ehninger, G., Heuser, M., Ganser, A., Pallaud, C., Gathmann, I., Krzykalla, J., Benner, A., Bloomfield, C.D., Thiede, C., Stone, R.M., Döhner, H. and Döhner, K.
Leukemia 36 (9): 2218-2227. September 2022

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K., Schmalbrock, L.K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J.S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

Precision medicine in myeloid malignancies.
Westermann, J. and Bullinger, L.
Seminars in Cancer Biology 84 : 153-169. September 2022

Concomitant cytotoxic effector differentiation of CD4(+) and CD8(+) T cells in response to EBV-Infected B cells.
Tamura, Y., Yamane, K., Kawano, Y., Bullinger, L., Wirtz, T., Weber, T., Sander, S., Ohki, S., Kitajima, Y., Okada, S., Rajewsky, K. and Yasuda, T.
Cancers 14 (17): 4118. 25 August 2022

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Zhai, Y., Singh, P., Dolnik, A., Brazda, P., Atlasy, N., Del Gaudio, N., Döhner, K., Döhner, H., Minucci, S., Martens, J., Altucci, L., Megchelenbrink, W., Bullinger, L. and Stunnenberg, H.G.
Molecular Cancer 21 (1): 166. 19 August 2022

The landscape of genetic aberrations in myxofibrosarcoma.
Takeuchi, Y., Yoshida, K., Halik, A., Kunitz, A., Suzuki, H., Kakiuchi, N., Shiozawa, Y., Yokoyama, A., Inoue, Y., Hirano, T., Yoshizato, T., Aoki, K., Fujii, Y., Nannya, Y., Makishima, H., Pfitzner, B.M., Bullinger, L., Hirata, M., Jinnouchi, K., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., Okamoto, T., Haga, H., Ogawa, S. and Damm, F.
International Journal of Cancer 151 (4): 565-577. 15 August 2022

Unified classification and risk-stratification in Acute Myeloid Leukemia.
Tazi, Y., Arango-Ossa, J.E., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S., Pradat, Y., Johnson, S.J., Hills, R., Dillon, R., Levine, M.F., Leongamornlert, D., Butler, A., Ganser, A., Bullinger, L., Döhner, K., Ottmann, O., Adams, R., Döhner, H., Campbell, P.J., Burnett, A.K., Dennis, M., Russell, N.H., Devlin, S.M., Huntly, B.J.P. and Papaemmanuil, E.
Nature Communications 13 (1): 4622. 8 August 2022

Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy.
Ihlow, J., Gross, S., Busack, L., Flörcken, A., Jesse, J., Schwarz, M., Neuendorff, N.R., von Brünneck, A.C., Anagnostopoulos, I., Türkmen, S., Blau, I.W., Burmeister, T., Horst, D., Bullinger, L. and Westermann, J.
Haematologica 107 (8): 1773-1785. August 2022

Application of precision medicine in clinical routine in haematology - challenges and opportunities.
Wästerlid, T., Cavelier, L., Haferlach, C., Konopleva, M., Fröhling, S., Östling, P., Bullinger, L., Fioretos, T. and Smedby, K.E.
Journal of Internal Medicine 292 (2): 243-261. August 2022

Long-term observation of the frequency of secondary colorectal cancer and other malignancies in tyrosine kinase inhibitor treated chronic myeloid leukemia patients and controls.
Winkelmann, N., Schwarz, M., Hildebrandt, B., Henke, O., Bullinger, L., Na, I.K., Stintzing, S. and le Coutre, P.
eJHaem: The Official Journal of the British Society for Haematology 3 (3): 949-953. August 2022

Rapid single-cell identification of Epstein-Barr virus-specific T-cell receptors for cellular therapy.
Lammoglia Cobo, M.F., Welters, C., Rosenberger, L., Leisegang, M., Dietze, K., Pircher, C., Penter, L., Gary, R., Bullinger, L., Takvorian, A., Moosmann, A., Dornmair, K., Blankenstein, T., Kammertöns, T., Gerbitz, A. and Hansmann, L.
Cytotherapy 24 (8): 818-826. August 2022

The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, A.C., Calvo, I.A., Cenzano, I., Olaverri, D., Cocera, M., San Martin-Uriz, P., Romero, J.P., Vilas-Zornoza, A., Vera, L., Gomez-Cebrian, N., Puchades-Carrasco, L., Lisi-Vega, L.E., Apaolaza, I., Valera, P., Guruceaga, E., Granero-Molto, F., Ripalda-Cemborain, P., Luck, T.J., Bullinger, L., Planes, F.J., Rifon, J.J., Méndez-Ferrer, S., Yusuf, R.Z., Pardo-Saganta, A., Prosper, F. and Saez, B.
Leukemia 36 (8): 1969-1979. August 2022

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
Grasedieck, S., Cabantog, A., MacPhee, L., Im, J., Ruess, C., Demir, B., Sperb, N., Rücker, F.G., Döhner, K., Herold, T., Pollack, J.R., Bullinger, L., Rouhi, A. and Kuchenbauer, F.
Haematologica 107 (8): 1758-1772. August 2022

Clonal hematopoiesis of indeterminate potential-related epigenetic age acceleration correlates with clonal hematopoiesis of indeterminate potential clone size in patients with high morbidity.
Feldkamp, J.D., Vetter, V.M., Arends, C.M., Lang, T.J.L., Bullinger, L., Damm, F., Demuth, I. and Frick, M.
Haematologica 107 (7): 1703-1708. July 2022

Flow cytometry can reliably capture gut microbial composition in healthy adults as well as dysbiosis dynamics in patients with aggressive B-cell non-Hodgkin lymphoma.
Schmiester, M., Maier, R., Riedel, R., Durek, P., Frentsch, M., Kolling, S., Mashreghi, M.F., Jenq, R., Zhang, L., Peterson, C.B., Bullinger, L., Chang, H.D. and Na, I.K.
Gut Microbes 14 (1): e2081475. 29 May 2022

Paired donor and recipient immunophenotyping in allogeneic hematopoietic stem cell transplantation: a cellular network approach.
Wittenbecher, F., Lesch, S., Kolling, S., Blau, I.W., Vuong, L., Borchert, F., Movasshagi, K., Tietze-Bürger, C., Penack, O., Ahn, J., Bullinger, L., Frentsch, M. and Na, I.K.
Frontiers in Immunology 13 : 874499. 23 May 2022

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F.L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M.D. and Subklewe, M.
Journal for ImmunoTherapy of Cancer 10 (5): e004475. 17 May 2022

Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.
Hernández-Malmierca, P., Vonficht, D., Schnell, A., Uckelmann, H.J., Bollhagen, A., Mahmoud, M.A.A., Landua, S.L., van der Salm, E., Trautmann, C., Raffel, S., Grünschläger, F., Lutz, R., Ghosh, M., Renders, S., Correia, N., Donato, E., Dixon, K.O., Hirche, C., Andresen, C., Robens, Cl., Werner, P.S., Boch, T., Eisel, D., Osen, W., Pilz, F., Przybylla, A., Klein, C., Buchholz, F., Milsom, M.D., Essers, M.A.G., Eichmüller, S.B., Hofmann, W.K., Nowak, D., Hübschmann, D., Hundemer, M., Thiede, C., Bullinger, L., Müller-Tidow, C., Armstrong, S.A., Trumpp, A., Kuchroo, V.K. and Haas, S.
Cell Stem Cell 29 (5): 760-775. 5 May 2022

Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).
Maschmeyer, G., Bullinger, L., Garcia-Vidal, C., Herbrecht, R., Maertens, J., Menna, P., Pagano, L., Thiebaut-Bertrand, A. and Calandra, T.
Leukemia 36 (5): 1215-1226. May 2022

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L. and Na, I.K.
OncoImmunology 11 (1): 2068109. 25 April 2022

EASIX and severe endothelial complications after CD19-directed CAR-T Cell therapy-a cohort study.
Korell, F., Penack, O., Mattie, M., Schreck, N., Benner, A., Krzykalla, J., Wang, Z., Schmitt, M., Bullinger, L., Müller-Tidow, C., Dreger, P. and Luft, T.
Frontiers in Immunology 13 : 877477. 8 April 2022

FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Raschzok, N., Stintzing, S., Heinemann, V., Rauch, G., Ricke, J., Guckenberger, M., Kurreck, A., Alig, A.H.S., Stahler, A., Bullinger, L., Schmelzle, M., Schöning, W., Lurje, G., Krenzien, F., Haase, O., Rau, B., Gebauer, B., Sauer, I.M., Pratschke, J. and Modest, D.P.
BMC Cancer 22 (1): 359. 2 April 2022

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus.
Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Della Porta, M.G., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., Gomes da Silva, M., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G. and Passamonti, F.
ESMO Open 7 (2): 100403. April 2022

Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9.
Christen, F., Hablesreiter, R., Hoyer, K., Hennch, C., Maluck-Böttcher, A., Segler, A., Madadi, A., Frick, M., Bullinger, L., Briest, F. and Damm, F.
Leukemia 36 (4): 1102-1110. April 2022

Refining AML treatment: the role of genetics in response and resistance evaluation to new agents.
Halik, A., Arends, C.M., Bullinger, L., Damm, F. and Frick, M.
Cancers 14 (7): 1689. 26 March 2022

Simultaneous genetic ablation of PD-1, LAG-3, and TIM-3 in CD8 T cells delays tumor growth and improves survival outcome.
Ciraolo, E., Althoff, S., Ruß, J., Rosnev, S., Butze, M., Pühl, M., Frentsch, M., Bullinger, L. and Na, I.K.
International Journal of Molecular Sciences 23 (6): 3207. 16 March 2022

Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Arends, C.M., Dimitriou, S., Stahler, A., Hablesreiter, R., Strzelecka, P.M., Stein, C.M., Tilgner, M., Saiki, R., Ogawa, S., Bullinger, L., Modest, D.P., Stintzing, S., Heinemann, V. and Damm, F.
Blood 139 (10): 1593-1597. 10 March 2022

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Y.L.D., Ramberger, E., Bohl, S.R., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., Gütschow, M., Döhner, H., Walther, W., Keller, U., Bullinger, L., Mertins, P. and Krönke, J.
Nature Communications 13 (1): 1009. 23 February 2022

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder, T.M., Schwarzer, A., Jayavelu, A.K., Hsu, C.J., Kirkpatrick, J., Döhner, K., Perner, F., Eifert, T., Huber, N., Arreba-Tutusaus, P., Dolnik, A., Assi, S.A., Nafria, M., Jiang, L., Dai, Y.T., Chen, Z., Chen, S.J., Kellaway, S.G., Ptasinska, A., Ng, E.S., Stanley, E.G., Elefanty, A.G., Buschbeck, M., Bierhoff, H., Brodt, S., Matziolis, G., Fischer, K.D., Hochhaus, A., Chen, C.W., Heidenreich, O., Mann, M., Lane, S.W., Bullinger, L., Ori, A., von Eyss, B., Bonifer, C. and Heidel, F.
Blood 139 (7): 1080-1097. 17 February 2022

Acute left ventricular insufficiency in a Burkitt Lymphoma patient with myocardial involvement and extensive local tumor cell lysis: a case report.
Schmiester, M., Tranter, E., Lorusso, A., Blaschke, F., Geisel, D., Bullinger, L., Damm, F. and Na, I.K.
BMC Cardiovascular Disorders 22 (1): 31. 4 February 2022

CEBPA mutations in AML: site matters.
Bullinger, L.
Blood 139 (1): 6-7. 6 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S., Bittner, A., Frick, M., Kase, J., Hoffmann, J., Trenker, C., Keller, U., Bogner, C., Hüttmann, A., Dürig, J., Janz, M., Mathas, S., Marks, R., Krohn, U., Na, I.K., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker, F.G., Du, L., Luck, T.J., Benner, A., Krzykalla, J., Gathmann, I., Voso, M.T., Amadori, S., Prior, T.W., Brandwein, J.M., Appelbaum, F.R., Medeiros, B.C., Tallman, M.S., Savoie, L., Sierra, J., Pallaud, C., Sanz, M.A., Jansen, J.H., Niederwieser, D., Fischer, T., Ehninger, G., Heuser, M., Ganser, A., Bullinger, L., Larson, R.A., Bloomfield, C.D., Stone, R.M., Döhner, H., Thiede, C. and Döhner, K.
Leukemia 36 (1): 90-99. January 2022

2021

Survey of long-term experiences of sperm cryopreservation in oncological and non-oncological patients: usage and reproductive outcomes of a large monocentric cohort.
Lackamp, N., Wilkemeyer, I., Jelas, I., Keller, U., Bullinger, L., Stintzing, S. and le Coutre, P.
Frontiers in Oncology 11 : 772809. 5 November 2021

Netboost: boosting-supported network analysis improves high-dimensional omics prediction in acute myeloid leukemia and Huntington's disease.
Schlosser, P., Knaus, J., Schmutz, M., Döhner, K., Plass, C., Bullinger, L., Claus, R., Binder, H., Lübbert, M. and Schumacher, M.
IEEE/ACM Transactions on Computational Biology and Bioinformatics 18 (6): 2635-2648. 1 November 2021

Survivin’ acute myeloid leukaemia - a personalised target for inv(16) patients.
Greiner, J., Brown, E., Bullinger, L., Hills, R.K., Morris, V., Döhner, H., Mills, K.I. and Guinn, B.A.
International Journal of Molecular Sciences 22 (19): 10482. 1 October 2021

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Bloehdorn, J., Braun, A., Taylor-Weiner, A., Jebaraj, B.M.C., Robrecht, S., Krzykalla, J., Pan, H., Giza, A., Akylzhanova, G., Holzmann, K., Scheffold, A., Johnston, H.E., Yeh, R.F., Klymenko, T., Tausch, E., Eichhorst, B., Bullinger, L., Fischer, K., Weisser, M., Robak, T., Schneider, C., Gribben, J., Dahal, L.N., Carter, M.J., Elemento, O., Landau, D.A., Neuberg, D.S., Cragg, M.S., Benner, A., Hallek, M., Wu, C.J., Döhner, H., Stilgenbauer, S. and Mertens, D.
Nature Communications 12 (1): 5395. 13 September 2021

58/w mit zunehmender psychomotorischer Verlangsamung und Zephalgien [58/f with increasing psychomotor retardation and headache].
Onken, J.S. and Bullinger, L.
Onkologe 27 : 79-84. September 2021

CD4+ T cell dependent B cell recovery and function after autologous hematopoietic stem cell transplantation.
Heck, C., Steiner, S., Kaebisch, E.M., Frentsch, M., Wittenbecher, F., Scheibenbogen, C., Hanitsch, L.G., Nogai, A., le Coutre, P., Bullinger, L., Blau, I.W. and Na, I.K.
Frontiers in Immunology 12 : 736137. September 2021

Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia.
Rapaport, F., Neelamraju, Y., Baslan, T., Hassane, D., Gruszczynska, A., de Massy, M.R., Farnoud, N., Haddox, S., Lee, T., Medina-Martinez, J., Sheridan, C., Thurmond, A., Becker, M., Bekiranov, S., Carroll, M., Moses Murdock, H., Valk, P.J.M., Bullinger, L., D’Andrea, R., Lowe, S.W., Neuberg, D., Levine, R.L., Melnick, A. and Garrett-Bakelman, F.E.
Leukemia 35 (9): 2688-2692. September 2021

The EHA Research Roadmap: Malignant Myeloid Diseases.
Döhner, H., Malcovati, L., Ossenkoppele, G.J., Hochhaus, A., Maria Vannucchi, A., Bullinger, L., Cervantes, F., Craddock, C., de Witte, T., Döhner, K., Dombret, H., Fenaux, P., Geissler, J., Germing, U., Guilhot, F., Harrison, C., Hellström-Lindberg, E., Passamonti, F., Sierra, J., Skoda, R. and Wierzbowska, A.
HemaSphere 5 (9): e635. September 2021

COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab.
Dimai, S., Semmler, L., Prabhu, A., Stachelscheid, H., Huettemeister, J., Klaucke, S.C., Lacour, P., Blaschke, F., Kruse, J., Parwani, A., Boldt, L.H., Bullinger, L., Pieske, B.M., Heinzel, F.R. and Hohendanner, F.
PLoS ONE 16 (8): e0255976. 19 August 2021

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch, M.E., Kast, R.E., Karpel-Massler, G., Mayer, B., Zolk, O., Schmitz, B., Scheuerle, A., Maier, L., Bullinger, L., Mayer-Steinacker, R., Schmidt, C., Zeiler, K., Elshaer, Z., Panther, P., Schmelzle, B., Hallmen, A., Dwucet, A., Siegelin, M.D., Westhoff, M.A., Beckers, K., Bouche, G. and Heiland, T.
Neuro-Oncology Advances 3 (1): vdab075. 7 August 2021

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient.
Bittner, A., Radke, J., Eurich, D., Wiener, E., Denker, S., Anagnostopoulos, I., Na, I.K., Heppner, F.L., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 62 (8): 2026-2029. August 2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., Chemnitz, J., Middeke, J.M., Weber, T., Holtick, U., Trappe, R., Pfannes, R., Liersch, R., Spoer, C., Fuxius, S., Gebauer, N., Caillé, L., Geer, T., Koenecke, C., Keller, U., Claus, R., Mougiakakos, D., Mayer, S., Huettmann, A., Pott, C., Trummer, A., Wulf, G., Brunnberg, U., Bullinger, L., Hess, G., Mueller-Tidow, C., Glass, B., Lenz, G., Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

Early bilirubinemia after allogeneic stem cell transplantation - an endothelial complication.
Dai, H., Penack, O., Radujkovic, A., Schult, D., Majer-Lauterbach, J., Blau, I.W., Bullinger, L., Jiang, S., Müller-Tidow, C., Dreger, P. and Luft, T.
Bone Marrow Transplantation 56 (7): 1573-1583. July 2021

Genome sequencing in myeloid cancers.
Dolnik, A., Schrezenmeier, J. and Bullinger, L.
New England Journal of Medicine 384 (25): e106. 24 June 2021

Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges.
Herda, S., Heimann, A., Obermayer, B., Ciraolo, E., Althoff, S., Ruß, J., Grunert, C., Busse, A., Bullinger, L., Pezzutto, A., Blankenstein, T., Beule, D. and Na, I.K.
International Journal of Cancer 148 (12): 3097-3110. 15 June 2021

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock, L.K., Dolnik, A., Cocciardi, S., Sträng, E., Theis, F., Jahn, N., Panina, E., Blätte, T.J., Herzig, J.K., Skambraks, S., Rücker, F.G., Gaidzik, V.I., Paschka, P., Fiedler, W., Salih, H.R., Wulf, G.G., Schroeder, T., Lübbert, M., Schlenk, R.F., Thol, F., Heuser, M., Larson, R.A., Ganser, A., Stunnenberg, H.G., Minucci, S., Stone, R.M., Bloomfield, C.D., Döhner, H., Döhner, K. and Bullinger, L.
Blood 137 (22): 3093-3104. 3 June 2021

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl, S.R., Schmalbrock, L.K., Bauhuf, I., Meyer, T., Dolnik, A., Szyska, M., Blätte, T.J., Knödler, S., Röhner, L., Miller, D., Kull, M., Langer, C., Döhner, H., Letai, A., Damm, F., Heckl, D., Bullinger, L. and Krönke, J.
Blood Advances 5 (9): 2391-2402. 11 May 2021

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser, M., Heida, B., Büttner, K., Wienecke, C.P., Teich, K., Funke, C., Brandes, M., Klement, P., Liebich, A., Wichmann, M., Neziri, B., Chaturvedi, A., Kloos, A., Mintzas, K., Gaidzik, V.I., Paschka, P., Bullinger, L., Fiedler, W., Heim, A., Puppe, W., Krauter, J., Döhner, K., Döhner, H., Ganser, A., Stadler, M., Hambach, L., Gabdoulline, R. and Thol, F.
Blood Advances 5 (9): 2294-2304. 11 May 2021

Clinical outcome of older adults with acute myeloid leukemia: an analysis of a large tertiary referral center over two decades.
Ihlow, J., Gross, S., Neuendorff, N.R., Busack, L., Herneth, A., Singh, A., Schwarz, M., Flörcken, A., Anagnostopoulos, I., Türkmen, S., Burmeister, T., Blau, I.W., Bullinger, L. and Westermann, J.
Journal of Geriatric Oncology 12 (4): 540-549. May 2021

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.
Giacopelli, B., Wang, M., Cleary, A., Wu, Y.Z., Schultz, A.R., Schmutz, M., Blachly, J.S., Eisfeld, A.K., Mundy-Bosse, B., Vosberg, S., Greif, P.A., Claus, R., Bullinger, L., Garzon, R., Coombes, K.R., Bloomfield, C.D., Druker, B.J., Tyner, J.W., Byrd, J.C. and Oakes, C.C.
Genome Research 31 (5): 747-761. May 2021

A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial.
Hoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., Striefler, J.K., Bischoff, S., Lohneis, P., Putter, H., Blau, O., Keilholz, U., Bullinger, L., Pelzer, U., Hummel, M., Riess, H., Ogawa, S., Sinn, M. and Damm, F.
EBioMedicine 66 : 103327. April 2021

Deregulated expression of circular RNAs in acute myeloid leukemia.
Lux, S., Blätte, T.J., Gillissen, B., Richter, A., Cocciardi, S., Skambraks, S., Schwarz, K., Schrezenmeier, H., Döhner, H., Döhner, K., Dolnik, A. and Bullinger, L.
Blood Advances 5 (5): 1490-1503. 9 March 2021

NEMHESYS - European perspective on the implementation of next-generation sequencing into clinical diagnostics.
Serramito-Gómez, I., Clarke, K.M., Rodríguez-Vicente, A.E., McGimpsey, J.E., Abáigar, M., Díez, C.B., Benito, R., Bullinger, L., Mills, K.I. and Hernández Rivas, J.M.
HemaSphere 5 (3): e541. March 2021

B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased.
Ihlow, J., Michaelis, E., Greuel, S., Heynol, V., Lehmann, A., Radbruch, H., Meinhardt, J., Miller, F., Herbst, H., Corman, V.M., Westermann, J., Bullinger, L., Horst, D., von Brünneck, A.C. and Elezkurtaj, S.
International Journal of Infectious Diseases 103 : 628-635. February 2021

Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.
Brandes, F., Striefler, J.K., Dörr, A., Schmiester, M., Märdian, S., Koulaxouzidis, G., Kaul, D., Behzadi, A., Thuss-Patience, P., Ahn, J., Pelzer, U., Bullinger, L. and Flörcken, A.
BMC Palliative Care 20 (1): 16. 14 January 2021

Gene expression profiling predicts sensitivity of chronic lymphocytic leukemia cells to dasatinib.
Blätte, T.J., Machnicki, M.M., Glodkowska-Mrowka, E., Dolnik, A., Karp, M., Karczmarczyk, A., Giannopoulos, K., Bullinger, L. and Stoklosa, T.
HemaSphere 5 (1): e514. January 2021

TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
Schmiester, M., Dolnik, A., Kornak, U., Pfitzner, B., Hummel, M., Treue, D., Hartmann, A., Agaimy, A., Weyerer, V., Lekaj, A., Brakemeier, S., Peters, R., Öllinger, R., Märdian, S., Bullinger, L., Striefler, J.K. and Flörcken, A.
Journal of Pathology Clinical Research 7 (1): 3-9. January 2021

Genomic landscape and clonal evolution of AML.
Noerenberg, D., Damm, F. and Bullinger, L.
In: Acute Myeloid Leukemia. Hematologic Malignancies . Springer, Cham, 103-118. ISBN 978-3-030-72675-1 2021

2020

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer, S., Weber, D., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Krönke, J., Theis, F., Rücker, F.G., Teleanu, M.V., Panina, E., Jahn, N., Herzig, J., Kubanek, L., Schrade, A., Göhring, G., Fiedler, W., Kindler, T, Schroeder, T., Mayer, K.T., Lübbert, M., Wattad, M., Götze, K.S., Horst, H.A., Koller, E., Wulf, G., Schleicher, J., Bentz, M., Krauter, J., Bullinger, L., Krzykalla, J., Benner, A., Schlenk, R.F., Thol, F., Heuser, M., Ganser, A., Döhner, H and Döhner, K.
Blood 136 (26): 3041-3050. 24 December 2020

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn, N., Terzer, T., Sträng, E., Dolnik, A., Cocciardi, S., Panina, E., Corbacioglu, A., Herzig, J., Weber, D., Schrade, A., Götze, K., Schröder, T., Lübbert, M., Wellnitz, D., Koller, E., Schlenk, R.F., Gaidzik, V.I., Paschka, P., Rücker, F.G., Heuser, M., Thol, F., Ganser, A., Benner, A., Döhner, H., Bullinger, L. and Döhner, K.
Blood Advances 4 (24): 6342-6352. 22 December 2020

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms.
Jayavelu, A.K., Schnöder, T.M., Perner, F., Herzog, C., Meiler, A., Krishnamoorthy, G., Huber, N., Mohr, J., Edelmann-Stephan, B., Austin, R., Brandt, S., Palandri, F., Schröder, N., Isermann, B., Edlich, F., Sinha, A.U., Ungelenk, M., Hübner, C.A., Zeiser, R., Rahmig, S., Waskow, C., Coldham, I., Ernst, T., Hochhaus, A., Jilg, S., Jost, P.J., Mullally, A., Bullinger, L., Mertens, P.R., Lane, S.W., Mann, M. and Heidel, F.H.
Nature 588 (7836): 157-163. 3 December 2020

A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial.
Janssen, M., Schäkel, U., Djuka Fokou, C., Krisam, J., Stermann, J., Kriegsmann, K., Haberbosch, I., Novotny, J.P., Weber, S., Vehreschild, M., Bornhäuser, M., Bullinger, L., Schmitt, M., Liebregts, T., Dreger, P., Lorenz, H.M., Plaszczyca, A., Bartenschlager, R., Müller, B., Kräusslich, H.G., Halama, N., Jäger, D., Schlenk, R.F., Leo, A., Meuer, S., Weigand, M.A., Motsch, J., Merle, U., Denkinger, C.M. and Müller-Tidow, C.
Trials 21 (1): 828. 6 October 2020

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Tausch, E., Beck, P., Schlenk, R.F., Jebaraj, B.M.C., Dolnik, A., Yosifov, D.Y., Hillmen, P., Offner, F., Janssens, A., Babu, K.G., Grosicki, S., Mayer, J., Panagiotidis, P., McKeown, A., Gupta, I.V., Skorupa, A., Pallaud, C., Bullinger, L., Mertens, D., Döhner, H. and Stilgenbauer, S.
Haematologica 105 (10): 2440-2447. October 2020

Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells.
Raffel, S., Klimmeck, D., Falcone, M., Demir, A., Pouya, A., Zeisberger, P., Lutz, C., Tinelli, M., Bischel, O., Bullinger, L., Thiede, C., Flörcken, A., Westermann, J., Ehninger, G., Ho, A.D., Müller-Tidow, C., Gu, Z., Herrmann, C., Krijgsveld, J., Trumpp, A. and Hansson, J.
Blood 136 (13): 1507-1519. 24 September 2020

Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers.
Yusuf, R.Z., Saez, B., Sharda, A., van Gastel, N., Yu, V.W.C., Baryawno, N., Scadden, E.W., Acharya, S., Chattophadhyay, S., Huang, C., Viswanathan, V., S'aulis, D., Cobert, J., Sykes, D.B., Keibler, M.A., Das, S., Hutchinson, J.N., Churchill, M., Mukherjee, S., Lee, D., Mercier, F., Doench, J., Bullinger, L., Logan, D.J., Schreiber, S., Stephanopoulos, G., Rizzo, W.B. and Scadden, D.T.
Blood 136 (11): 1303-1316. 10 September 2020

Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.
In't Hout, F.E.M., Gerritsen, M., Bullinger, L., Van der Reijden, B.A., Huls, G., Vellenga, E. and Jansen, J.H.
Haematologica 105 (9): e454-457. 1 September 2020

The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia.
Grasedieck, S., Ruess, C., Krowiorz, K., Lux, S., Pochert, N., Schwarzer, A., Klusmann, J.H., Jongen-Lavrencic, M., Herold, T., Bullinger, L., Pollack, J.R., Rouhi, A. and Kuchenbauer, F.
Haematologica 105 (9): e448-e453. September 2020

Endothelial damage and dysfunction in acute graft-versus-host disease.
Cordes, S., Mokhtari, Z., Bartosova, M., Mertlitz, S., Riesner, K., Shi, Y., Mengwasser, J., Kalupa, M., McGeary, A., Schleifenbaum, J., Schrezenmeier, J., Bullinger, L., Diaz-Ricart, M., Palomo, M., Carrreras, E., Beutel, G., Schmitt, C.P., Beilhack, A. and Penack, O.
Haematologica 106 (8): 2147-2160. 1 August 2020

Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber, C., Correia, N., Trumpp, A., Rieger, M.A., Dolnik, A., Bullinger, L., Roeder, I. and Seifert, M.
Scientific Reports 10 (1): 12761. 29 July 2020

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.
Becker, H., Pfeifer, D., Ihorst, G., Pantic, M., Wehrle, J., Rüter, B.H., Bullinger, L., Hackanson, B., Germing, U., Kuendgen, A., Platzbecker, U., Döhner, K., Ganser, A., Hagemeijer, A., Wijermans, P.W., Döhner, H., Duyster, J. and Lübbert, M.
Annals of Hematology 99 (7): 1551-1560. July 2020

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch, E., Schneider, C., Robrecht, S., Zhang, C., Dolnik, A., Bloehdorn, J., Bahlo, J., Al-Sawaf, O., Ritgen, M., Fink, A.M., Eichhorst, B., Kreuzer, K.A., Tandon, M., Humphrey, K., Jiang, Y., Schary, W., Bullinger, L., Mertens, D., Lurà, M.P., Kneba, M., Döhner, H., Fischer, K., Hallek, M. and Stilgenbauer, S.
Blood 135 (26): 2402-2412. 25 June 2020

Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting.
Lang, K.M., Harrison, K.L., Williamson, P.R., Huntly, B.J.P., Ossenkoppele, G., Geissler, J., Bereczky, T., Hernández-Rivas, J.M., Chevrou-Séverac, H., Goodbody, R., Schulze-Rath, R. and Bullinger, L.
Trials 21 (1): 437. 27 May 2020

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.
Edelmann, J., Holzmann, K., Tausch, E., Saunderson, E.A., Jebaraj, B.M.C., Steinbrecher, D., Dolnik, A., Blätte, T.J., Landau, D.A., Saub, J., Estenfelder, S., Ibach, S., Cymbalista, F., Leblond, V., Delmer, A., Bahlo, J., Robrecht, S., Fischer, K., Goede, V., Bullinger, L., Wu, C.J., Mertens, D., Ficz, G., Gribben, J.G., Hallek, M., Döhner, H. and Stilgenbauer, S.
Haematologica 105 (5): 1379-1390. May 2020

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition.
Greiner, J., Götz, M., Hofmann, S., Schrezenmeier, H., Wiesneth, M., Bullinger, L., Döhner, H. and Schneider, V.
Cancer Immunology Immunotherapy 69 (4): 629-640. April 2020

Functional classification of TP53 mutations in acute myeloid leukemia.
Dutta, S., Pregartner, G., Rücker, F.G., Heitzer, E., Zebisch, A., Bullinger, L., Berghold, A., Döhner, K. and Sill, H.
Cancers 12 (3): 637. 10 March 2020

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
Agrawal, M., Schwarz, P., Giaimo, B.D., Bedzhov, I., Corbacioglu, A., Weber, D., Gaidzik, V.I., Jahn, N., Rücker, F.G., Schroeder, T., Kindler, T., Wattad, M., Götze, K., Lübbert, M., Salwender, H., Ringhoffer, M., Lange, E., Koller, E., Thol, F., Heuser, M., Ganser, A., Bullinger, L., Paschka, P., Döhner, H., Geiger, H., Borggrefe, T., Döhner, K. and Oswald, F.
Leukemia 34 (2): 630-634. February 2020

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
Meyer, T., Jahn, N., Lindner, S., Röhner, L., Dolnik, A., Weber, D., Scheffold, A., Köpff, S., Paschka, P., Gaidzik, V.I., Heckl, D., Wiese, S., Ebert, B.L., Döhner, H., Bullinger, L., Döhner, K. and Krönke, J.
Leukemia 34 (2): 404-415. February 2020

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang, S., Penack, O., Terzer, T., Schult, D., Majer-Lauterbach, J., Radujkovic, A., Blau, I.W., Bullinger, L., Müller-Tidow, C., Dreger, P. and Luft, T.
Haematologica 106 (2): 446-453. February 2020

Therapeutic targeting of preleukemia cells in a mouse model of mutant acute myeloid leukemia.
Uckelmann, H.J., Kim, S.M., Wong, E.M., Hatton, C., Giovinazzo, H., Gadrey, J.Y., Krivtsov, A.V., Rücker, F.G., Döhner, K., McGeehan, G.M., Levine, R.L., Bullinger, L., Vassiliou, G.S. and Armstrong, S.A.
Science 367 (6477): 586-590. 31 January 2020

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
Striefler, J.K., Brandes, F., Baur, A., Pfitzner, B.M., Kaul, D., Rau, D., Dörr, A., Schmiester, M., Koulaxouzidis, G., Bullinger, L., Märdian, S. and Flörcken, A.
BMC Cancer 20 (1): 68. 29 January 2020

Single-cell analysis based dissection of clonality in myelofibrosis.
Mylonas, E., Yoshida, K., Frick, M., Hoyer, K., Christen, F., Kaeda, J., Obenaus, M., Noerenberg, D., Hennch, C., Chan, W., Ochi, Y., Shiraishi, Y., Shiozawa, Y., Zenz, T., Oakes, C.C., Sawitzki, B., Schwarz, M., Bullinger, L., le Coutre, P., Rose-Zerilli, M.J.J., Ogawa, S. and Damm, F.
Nature Communications 11 (1): 73. 7 January 2020

2019

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Rücker, F.G., Agrawal, M., Corbacioglu, A., Weber, D., Kapp-Schwoerer, S., Gaidzik, V.I., Jahn, N., Schroeder, T., Wattad, M., Lübbert, M., Koller, E., Kindler, T., Götze, K., Ringhoffer, M., Westermann, J., Fiedler, W., Horst, H.A., Greil, R., Schroers, R., Mayer, K., Heinicke, T., Krauter, J., Schlenk, R.F., Thol, F., Heuser, M., Ganser, A., Bullinger, L., Paschka, P., Döhner, H. and Döhner, K.
Blood 134 (19): 1608-1618. 7 November 2019

Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.
Doescher, J., Weissinger, S.E., Schönsteiner, S.S., Lisson, C., Bullinger, L., Barth, T.F., Leithäuser, F., Mueller-Richter, U., Laban, S., Hoffmann, T.K., Möller, P., Lennerz, J.K. and Schuler, P.J.
Immunotherapy 11 (14): 1193-1203. October 2019

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Weller, J., Tzaridis, T., Mack, F., Steinbach, J.P., Schlegel, U., Hau, P., Krex, D., Grauer, O., Goldbrunner, R., Bähr, O., Uhl, M., Seidel, C., Tabatabai, G., Brehmer, S., Bullinger, L., Galldiks, N., Schaub, C., Kebir, S., Stummer, W., Simon, M., Fimmers, R., Coch, C., Glas, M., Herrlinger, U. and Schäfer, N.
Lancet Oncology 20 (10): 1444-1453. October 2019

getITD for FLT3-ITD-based MRD monitoring in AML.
Blätte, T.J., Schmalbrock, L.K., Skambraks, S., Lux, S., Cocciardi, S., Dolnik, A., Döhner, H., Döhner, K. and Bullinger, L.
Leukemia 33 (10): 2535-2539. October 2019

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information.
Ettrich, T.J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T.J., Schmidt, S.A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R., Kleger, A., Bullinger, L., Seufferlein, T. and Berger, A.W.
Scientific Reports 9 (1): 13261. 13 September 2019

Venetoclax resistance and acquired mutations in chronic lymphocytic leukemia.
Tausch, E., Close, W., Dolnik, A., Bloehdorn, J., Chyla, B., Bullinger, L., Döhner, H., Mertens, D. and Stilgenbauer, S.
Haematologica 104 (9): e434-e437. September 2019

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold, A., Jebaraj, B.M.C., Tausch, E., Bloehdorn, J., Ghia, P., Yahiaoui, A., Dolnik, A., Blätte, T.J., Bullinger, L., Dheenadayalan, R.P., Li, L., Schneider, C., Chen, S.S., Chiorazzi, N., Dietrich, S., Seiffert, M., Tannheimer, S., Döhner, H., Mertens, D. and Stilgenbauer, S.
Blood 134 (6): 534-547. 8 August 2019

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.
Jakobsen, J.S., Laursen, L.G., Schuster, M.B., Pundhir, S., Schoof, E., Ge, Y., d'Altri, T., Vitting-Seerup, K., Rapin, N., Gentil, C., Jendholm, J., Theilgaard-Mönch, K., Reckzeh, K., Bullinger, L., Döhner, K., Hokland, P., Fitzgibbon, J. and Porse, B.T.
Science Advances 5 (7): eaaw4304. July 2019

NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
Sasca, D., Szybinski, J., Schüler, A., Shah, V., Heidelberger, J., Haehnel, P.S., Dolnik, A., Kriege, O., Fehr, E.M., Gebhardt, W.H., Reid, G., Scholl, C., Theobald, M., Bullinger, L., Beli, P. and Kindler, T.
Blood 133 (21): 2305-2319. 23 May 2019

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.
Cocciardi, S., Dolnik, A., Kapp-Schwoerer, S., Rücker, F.G., Lux, S., Blätte, T.J., Skambraks, S., Krönke, J., Heidel, F.H., Schnöder, T.M., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Teleanu, V., Göhring, G., Thol, F., Heuser, M., Ganser, A., Weber, D., Sträng, E., Kestler, H.A., Döhner, H., Bullinger, L. and Döhner, K.
Nature Communications 10 (1): 2031. 2 May 2019

Retroperitoneal hematoma after bone marrow biopsy: the first cut should not be the deepest.
Wojciechowski, A., Duckert, M., Hartmann, J., Bullinger, L. and Matzdorff, A.
Oncology Research and Treatment 42 (5): 283-288. May 2019

New targeted agents in acute myeloid leukemia: new hope on the rise.
Bohl, S.R., Bullinger, L. and Rücker, F.G.
International Journal of Molecular Sciences 20 (8) 23 April 2019

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Jutzi, J.S., Basu, T., Pellmann, M., Kaiser, S., Steinemann, D., Sanders, M.A., Hinai, A.S.A., Zeilemaker, A., Bojtine Kovacs, S., Koellerer, C., Ostendorp, J., Aumann, K., Wang, W., Raffoux, E., Cassinat, B., Bullinger, L., Schlegelberger, B., Valk, P.J.M. and Pahl, H.L.
Blood 133 (16): 1766-1777. 18 April 2019

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Basheer, F., Giotopoulos, G., Meduri, E., Yun, H., Mazan, M., Sasca, D., Gallipoli, P., Marando, L., Gozdecka, M., Asby, R., Sheppard, O., Dudek, M., Bullinger, L., Döhner, H., Dillon, R., Freeman, S., Ottmann, O., Burnett, A., Russell, N., Papaemmanuil, E., Hills, R., Campbell, P., Vassiliou, G.S.. and Huntly, B.J.P.
Journal of Experimental Medicine 216 (4): 966-981. 1 April 2019

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Christen, F., Hoyer, K., Yoshida, K., Hou, H.A., Waldhueter, N., Heuser, M., Hills, R.K., Chan, W., Hablesreiter, R., Blau, O., Ochi, Y., Klement, P., Chou, W.C., Blau, I.W., Tang, J.L., Zemojtel, T., Shiraishi, Y., Shiozawa, Y., Thol, F., Ganser, A., Löwenberg, B., Linch, D.C., Bullinger, L., Valk, P.J.M., Tien, H.F., Gale, R.E., Ogawa, S. and Damm, F.
Blood 133 (10): 1140-1151. 7 March 2019

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Simonetti, G., Padella, A., do Valle, I.F., Fontana, M.C., Fonzi, E., Bruno, S., Baldazzi, C., Guadagnuolo, V., Manfrini, M., Ferrari, A., Paolini, S., Papayannidis, C., Marconi, G., Franchini, E., Zuffa, E., Laginestra, M.A., Zanotti, F., Astolfi, A., Iacobucci, I., Bernardi, S., Sazzini, M., Ficarra, E., Hernandez, J.M., Vandenberghe, P., Cools, J., Bullinger, L., Ottaviani, E., Testoni, N., Cavo, M., Haferlach, T., Castellani, G., Remondini, D. and Martinelli, G.
Cancer 125 (5): 712-725. 1 March 2019

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J.P., Schlegel, U., Sabel, M., Hau, P., Kortmann, R.D., Krex, D., Grauer, O., Goldbrunner, R., Schnell, O., Bähr, O., Uhl, M., Seidel, C., Tabatabai, G., Kowalski, T., Ringel, F., Schmidt-Graf, F., Suchorska, B., Brehmer, S., Weyerbrock, A., Renovanz, M., Bullinger, L., Galldiks, N., Vajkoczy, P., Misch, M., Vatter, H., Stuplich, M., Schäfer, N., Kebir, S., Weller, J., Schaub, C., Stummer, W., Tonn, J.C., Simon, M., Keil, V.C., Nelles, M., Urbach, H., Coenen, M., Wick, W., Weller, M., Fimmers, R., Schmid, M., Hattingen, E., Pietsch, T., Coch, C. and Glas, M.
Lancet 393 (10172): 678-688. 16 February 2019

IDH2 inhibition: another piece to the puzzle.
Bullinger, L.
Blood 133 (7): 625-626. 14 February 2019

Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation.
Frick, M., Chan, W., Arends, C.M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., Galan-Sousa, J., Noerenberg, D., Wais, V., Stadler, M., Yoshida, K., Schetelig, J., Schuler, E., Thol, F., Clappier, E., Christopeit, M., Ayuk, F., Bornhäuser, M., Blau, I.W., Ogawa, S., Zemojtel, T., Gerbitz, A., Wagner, E.M., Spriewald, B.M., Schrezenmeier, H., Kuchenbauer, F., Kobbe, G., Wiesneth, M., Koldehoff, M., Socié, G., Kroeger, N., Bullinger, L., Thiede, C. and Damm, F.
Journal of Clinical Oncology 37 (5): 375-385. 10 February 2019

Analysis of the CDK4/6 cell cycle pathway in leiomyosarcomas as a potential target for inhibition by palbociclib.
Böhm, M.J., Marienfeld, R., Jäger, D., Mellert, K., von Witzleben, A., Brüderlein, S., Wittau, M., von Baer, A., Schultheiss, M., Mayer-Steinacker, R., Rücker, F.G., Möller, P., Bullinger, L. and Barth, T.F.E.
Sarcoma 2019 : 3914232. 21 January 2019

2018

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., Ling, V., Green, J., Austin, R., Kazakoff, S., Waddell, N., Hesson, L.B., Pimanda, J.E., Stegelmann, F., Bullinger, L., Döhner, K., Rampal, R.K., Heckl, D., Hill, G.R. and Lane, S.W.
Blood 132 (26): 2707-2721. 27 December 2018

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Döhner, H., Dolnik, A., Tang, L., Seymour, J.F., Minden, M.D., Stone, R.M., Del Castillo, T.B., Al-Ali, H.K., Santini, V., Vyas, P., Beach, C L., MacBeth, K.J., Skikne, B.S., Songer, S., Tu, N., Bullinger, L. and Dombret, H.
Leukemia 32 (12): 2546-2557. December 2018

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.
Zajac, M., Zaleska, J., Dolnik, A., Bullinger, L. and Giannopoulos, K.
British Journal of Haematology 183 (5): 822-825. December 2018

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol, F., Gabdoulline, R., Liebich, A., Klement, P., Schiller, J., Kandziora, C., Hambach, L., Stadler, M., Koenecke, C., Flintrop, M., Pankratz, M., Wichmann, M., Neziri, B., Büttner, K., Heida, B., Klesse, S., Chaturvedi, A., Kloos, A., Göhring, G., Schlegelberger, B., Gaidzik, V.I., Bullinger, L., Fiedler, W., Heim, A., Hamwi, I., Eder, M., Krauter, J., Schlenk, R.F., Paschka, P., Döhner, K., Döhner, H., Ganser, A. and Heuser, M.
Blood 132 (16): 1703-1713. 18 October 2018

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
L'Abbate, A., Tolomeo, D., Cifola, I., Severgnini, M., Turchiano, A., Augello, B., Squeo, G., D'Addabbo, P., Traversa, D., Daniele, G., Lonoce, A., Pafundi, M., Carella, M., Palumbo, O., Dolnik, A., Muehlematter, D., Schoumans, J., Van Roy, N., De Bellis, G., Martinelli, G., Merla, G., Bullinger, L., Haferlach, C. and Storlazzi, C.T.
Leukemia 32 (10): 2152-2166. October 2018

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Rudat, S., Pfaus, A., Cheng, Y.Y., Holtmann, J., Ellegast, J.M., Bühler, C., Marcantonio, D.D., Martinez, E., Göllner, S., Wickenhauser, C., Müller-Tidow, C., Lutz, C., Bullinger, L., Milsom, M.D., Sykes, S.M., Fröhling, S. and Scholl, C.
Leukemia 32 (10): 2189-2202. October 2018

Circular RNAs in cancer.
Lux, S. and Bullinger, L.
Advances in Experimental Medicine and Biology 1087 : 215-230. 28 September 2018

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede, S., Nieborowska-Skorska, M., Sullivan-Reed, K., Dasgupta, Y., Podszywalow-Bartnicka, P., Le, B.V., Solecka, M., Lian, Z., Belyaeva, E.A., Nersesyan, A., Machnicki, M.M., Toma, M., Chatain, N., Rydzanicz, M., Zhao, H., Jelinek, J., Piwocka, K., Sliwinski, T., Stoklosa, T., Ploski, R., Fischer, T., Sykes, S.M., Koschmieder, S., Bullinger, L., Valent, P., Wasik, M.A., Huang, J. and Skorski, T.
Blood 132 (1): 67-77. 5 July 2018

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Paschka, P., Schlenk, R.F., Weber, D., Benner, A., Bullinger, L., Heuser, M., Gaidzik, V.I., Thol, F., Agrawal, M., Teleanu, V., Lübbert, M., Fiedler, W., Radsak, M., Krauter, J., Horst, H.A., Greil, R., Mayer, K., Kündgen, A., Martens, U., Heil, G., Salih, H.R., Hertenstein, B., Schwänen, C., Wulf, G., Lange, E., Pfreundschuh, M., Ringhoffer, M., Girschikofsky, M., Heinicke, T., Kraemer, D., Göhring, G., Ganser, A., Döhner, K. and Döhner, H.
Leukemia 32 (7): 1621-1630. July 2018

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
Gozdecka, M., Meduri, E., Mazan, M., Tzelepis, K., Dudek, M., Knights, A.J., Pardo, M., Yu, L., Choudhary, J.S., Metzakopian, E., Iyer, V., Yun, H., Park, N., Varela, I., Bautista, R., Collord, G., Dovey, O., Garyfallos, D.A., De Braekeleer, E., Kondo, S., Cooper, J., Göttgens, B., Bullinger, L., Northcott, P.A., Adams, D., Vassiliou, G.S. and Huntly, B.J.P.
Nature Genetics 50 (6): 883-894. June 2018

Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl, S.R., Bullinger, L. and Rücker, F.G.
Expert Review of Hematology 11 (5): 361-371. May 2018

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.
Mohr, J., Dash, B.P., Schnoeder, T.M., Wolleschak, D., Herzog, C., Tubio Santamaria, N., Weinert, S., Godavarthy, S., Zanetti, C., Naumann, M., Hartleben, B., Huber, T.B., Krause, D.S., Kähne, T., Bullinger, L. and Heidel, F.H.
Leukemia 32 (5): 1211-1221. May 2018

MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.
Frech, M., Teichler, S., Feld, C., Bouchard, C., Berberich, H., Sorg, K., Mernberger, M., Bullinger, L., Bauer, U.M. and Neubauer, A.
Oncotarget 9 (32): 22423-22435. 27 April 2018

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.
Schneider, E., Staffas, A., Röhner, L., Malmberg, E.D., Ashouri, A., Krowiorz, K., Pochert, N., Miller, C., Wei, S.Y., Arabanian, L., Buske, C., Döhner, H., Bullinger, L., Fogelstrand, L., Heuser, M., Döhner, K., Xiang, P., Ruschmann, J., Petriv, O.I., Heravi-Moussavi, A., Hansen, C.L., Hirst, M., Humphries, R.K., Rouhi, A., Palmqvist, L. and Kuchenbauer, F.
Haematologica 103 (2): 246-255. February 2018

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.
Jeck, J., Kassubek, R., Coburger, J., Edenhofer, S., Schönsteiner, S.S., Ludolph, A.C., Schmitz, B., Engelke, J., Mayer-Steinacker, R., Lewerenz, J. and Bullinger, L.
Therapeutic Advances in Neurological Disorders 11 : 1756285617753597. 21 January 2018

Chromothripsis is linked to alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.
Rücker, F.G., Dolnik, A., Blätte, T.J., Teleanu, V., Ernst, A., Thol, F., Heuser, M., Ganser, A., Döhner, H., Döhner, K. and Bullinger, L.
Haematologica 103 (1): e17-e20. January 2018

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Gaidzik, V.I., Weber, D., Paschka, P., Kaumanns, A., Krieger, S., Corbacioglu, A., Krönke, J., Kapp-Schwoerer, S., Krämer, D., Horst, H.A., Schmidt-Wolf, I., Held, G., Kündgen, A., Ringhoffer, M., Götze, K., Kindler, T., Fiedler, W., Wattad, M., Schlenk, R.F., Bullinger, L., Teleanu, V., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Döhner, H. and Döhner, K.
Leukemia 32 (1): 30-37. January 2018

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.
Wais, V., Kündgen, L., Bohl, S.R., von Harsdorf, S., Schlenk, R.F., Döhner, K., Teleanu, V., Bullinger, L., Nguyen, T.M., Drognitz, K., Moulin, J.C., Binnenhei, M., Bentz, M., Döhner, H., Bunjes, D., Kuchenbauer, F. and Ringhoffer, M.
Bone marrow transplantation 53 (1): 94-96. January 2018

The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.
Nickel, K., Renovanz, M., König, J., Stöckelmaier, L., Hickmann, A.K., Nadji-Ohl, M., Engelke, J., Weimann, E., Freudenstein, D., Ganslandt, O., Bullinger, L., Wirtz, C.R. and Coburger, J.
Neurosurgical Review 41 (1): 207-219. January 2018

2017

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
Nagel, G., Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H.R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H.A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V.I., Paschka, P., Döhner, K., Ganser, A., Döhner, H. and Schlenk, R.F.
Annals of Hematology 96 (12): 1993-2003. 1 December 2017

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
Greiner, J., Hofmann, S., Schmitt, M., Götz, M., Wiesneth, M., Schrezenmeier, H., Bunjes, D., Döhner, H. and Bullinger, L.
Haematologica 102 (12): e499-e501. December 2017

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.
Hirsch, S., Blätte, T.J., Grasedieck, S., Cocciardi, S., Rouhi, A., Jongen-Lavrencic, M., Paschka, P., Krönke, J., Gaidzik, V.I., Döhner, H., Schlenk, R.F., Kuchenbauer, F., Döhner, K., Dolnik, A. and Bullinger, L.
Haematologica 102 (12): 2039-2047. December 2017

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., Bullinger, L., Poschet, G., Nonnenmacher, Y., Barnert, A., Bahr, C., Zeisberger, P., Przybylla, A., Sohn, M., Tönjes, M., Erez, A., Adler, L., Jensen, P., Scholl, C., Fröhling, S., Cocciardi, S., Wuchter, P., Thiede, C., Flörcken, A., Westermann, J., Ehninger, G., Lichter, P., Hiller, K., Hell, R., Herrmann, C., Ho, A.D., Krijgsveld, J., Radlwimmer, B. and Trumpp, A.
Nature 551 (7680): 384-388. 16 November 2017

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.
Zajac, M., Dolnik, A., Stasiak, G., Zaleska, J., Kielbus, M., Czapinski, J., Schunn, M., Correa, S.C., Glodkowska-Mrowka, E., Sundaram, R.C., Jankowska-Lecka, O., Schlenk, R.F., Döhner, H., Döhner, K., Stepulak, A., Bullinger, L. and Giannopoulos, K.
Oncotarget 8 (56): 95163-95175. 10 November 2017

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.
Herzig, J.K., Bullinger, L., Tasdogan, A., Zimmermann, P., Schlegel, M., Teleanu, V., Weber, D., Rücker, F.G., Paschka, P., Dolnik, A., Schneider, E., Kuchenbauer, F., Heidel, F.H., Buske, C., Döhner, H., Döhner, K. and Gaidzik, V.I.
Oncotarget 8 (56): 95038-95053. 10 November 2017

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
Thiel, V.N., Giaimo, B.D., Schwarz, P., Soller, K., Vas, V., Bartkuhn, M., Blätte, T.J., Döhner, K., Bullinger, L., Borggrefe, T., Geiger, H. and Oswald, F.
Leukemia 31 (11): 2491-2502. November 2017

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.
Yalcin, A., Kovarbasic, M., Wehrle, J., Claus, R., Becker, H., Abdelkarim, M., Gaidzik, V.I., Schmidts, A., Wäsch, R., Pahl, H.L., Döhner, K., Bullinger, L., Duyster, J., Lübbert, M. and Hackanson, B.
Experimental Hematology 55 : 76-85. November 2017

Partitioned learning of deep Boltzmann machines for SNP data.
Hess, M., Lenz, S., Blätte, T.J., Bullinger, L. and Binder, H.
Bioinformatics 33 (20): 3173-3180. October 2017

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.
Bohl, S.R., Dolnik, A., Jensen, T., Lang, K.M., Hackanson, B., Gaidzik, V.I., Paschka, P., Knudsen, S., Döhner, K., Döhner, H., Claus, R., Lübbert, M. and Bullinger, L.
Leukemia & Lymphoma 58 (9): 2264-2267. 2 September 2017

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Nieborowska-Skorska, M., Sullivan, K., Dasgupta, Y., Podszywalow-Bartnicka, P., Hoser, G., Maifrede, S., Martinez, E., Di Marcantonio, D., Bolton-Gillespie, E., Cramer-Morales, K., Lee, J., Li, M., Slupianek, A., Gritsyuk, D., Cerny-Reiterer, S., Seferynska, I., Stoklosa, T., Bullinger, L., Zhao, H., Gorbunova, V., Piwocka, K., Valent, P., Civin, C.I., Muschen, M., Dick, J.E., Wang, J.C., Bhatia, S., Bhatia, R., Eppert, K., Minden, M.D., Sykes, S.M. and Skorski, T.
Journal of Clinical Investigation 127 (6): 2392-2406. 1 June 2017

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol, F., Klesse, S., Köhler, L., Gabdoulline, R., Kloos, A., Liebich, A., Wichmann, M., Chaturvedi, A., Fabisch, J., Gaidzik, V.I., Paschka, P., Bullinger, L., Bug, G., Serve, H., Göhring, G., Schlegelberger, B., Lübbert, M., Kirchner, H., Wattad, M., Kraemer, D., Hertenstein, B., Heil, G., Fiedler, W., Krauter, J., Schlenk, R.F., Döhner, K., Döhner, H., Ganser, A. and Heuser, M.
Leukemia 31 (6): 1286-1295. June 2017

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V., Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., Mügge, L.O., Straka, C., Engelhardt, M., Döhner, H., Einsele, H., Bassermann, F., Bargou, R., Knop, S. and Langer, C.
Leukemia 31 (6): 1363-1367. June 2017

Novel treatment options in head and neck cancer.
Schuler, P.J., Laban, S., Doescher, J., Bullinger, L. and Hoffmann, T.K.
Oncology Research and Treatment 40 (6): 342-346. June 2017

Therapy for recurrent high-grade gliomas: results of a prospective multicenter study on health-related quality of life.
Stöckelmaier, L., Renovanz, M., König, J., Nickel, K., Hickmann, A.K., Mayer-Steinacker, R., Nadji-Ohl, M., Ganslandt, O., Bullinger, L., Wirtz, C.R. and Coburger, J.
World Neurosurgery 102 : 383-399. June 2017

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Hiller, J.K., Schmoor, C., Gaidzik, V.I., Schmidt-Salzmann, C., Yalcin, A., Abdelkarim, M., Blagitko-Dorfs, N., Döhner, K., Bullinger, L., Duyster, J., Lübbert, M. and Hackanson, B.
Annals of Hematology 96 (4): 559-565. April 2017

Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.
Kassubek, R., Bullinger, L., Kassubek, J., Dreyhaupt, J., Ludolph, A.C., Althaus, K. and Lewerenz, J.
Journal of Neurology 264 (4): 781-791. April 2017

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.
Jahn, N., Agrawal, M., Bullinger, L., Weber, D., Corbacioglu, A., Gaidzik, V.I., Schmalbrock, L., Thol, F., Heuser, M., Krauter, J., Göhring, G., Kündgen, A., Fiedler, W., Wattad, M., Held, G., Köhne, C.H., Horst, H.A., Lübbert, M., Ganser, A., Schlenk, R.F., Döhner, H., Döhner, K. and Paschka, P.
Leukemia 31 (4): 1012-1015. April 2017

Genomics of acute myeloid leukemia diagnosis and pathways.
Bullinger, L., Döhner, K. and Döhner, H.
Journal of Clinical Oncology 35 (9): 934-946. 20 March 2017

Precision oncology for acute myeloid leukemia using a knowledge bank approach.
Gerstung, M., Papaemmanuil, E., Martincorena, I., Bullinger, L., Gaidzik, V.I., Paschka, P., Heuser, M., Thol, F., Bolli, N., Ganly, P., Ganser, A., McDermott, U., Döhner, K., Schlenk, R.F., Döhner, H. and Campbell, P.J.
Nature Genetics 49 (3): 332-340. March 2017

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
Qu, Y., Siggens, L., Cordeddu, L., Gaidzik, V.I., Karlsson, K., Bullinger, L., Döhner, K., Ekwall, K., Lehmann, S. and Lennartsson, A.
Blood 129 (7): e13-e25. 16 February 2017

Response evaluation in head and neck oncology: definition and prediction.
Hoffmann, T.K., Schuler, P.J., Laban, S., Grässlin, R., Beer, M., Beer, A.J., Friebe-Hoffmann, U., Bullinger, L., Möller, P. and Wiegel, T.
ORL 79 (1-2): 14-23. February 2017

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi, A., Miller, C., Grasedieck, S., Reinhart, S., Stolze, B., Döhner, H., Kuchenbauer, F., Bullinger, L., Fröhling, S. and Scholl, C.
Oncotarget 8 (5): 7678-7690. 31 January 2017

2016

MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia.
Krowiorz, K., Ruschmann, J., Lai, C., Ngom, M., Maetzig, T., Martins, V., Scheffold, A., Schneider, E., Pochert, N., Miller, C., Palmqvist, L., Staffas, A., Mulaw, M., Bohl, S.R., Buske, C., Heuser, M., Kraus, J., O'Neill, K., Hansen, C.L., Petriv, O.I., Kestler, H., Döhner, H., Bullinger, L., Döhner, K., Humphries, R.K., Rouhi, A. and Kuchenbauer, F.
Blood Cancer Journal 6 (12): e508. December 2016

The genomic landscape of core-binding factor acute myeloid leukemias.
Faber, Z.J., Chen, X., Gedman, A.L., Boggs, K., Cheng, J., Ma, J., Radtke, I., Chao, J.R., Walsh, M.P., Song, G., Andersson, A.K., Dang, J., Dong, L., Liu, Y., Huether, R., Cai, Z., Mulder, H., Wu, G., Edmonson, M., Rusch, M., Qu, C., Li, Y., Vadodaria, B., Wang, J., Hedlund, E., Cao, X., Yergeau, D., Nakitandwe, J., Pounds, S.B., Shurtleff, S., Fulton, R.S., Fulton, L.L., Easton, J., Parganas, E., Pui, C.H., Rubnitz, J.E., Ding, L., Mardis, E.R., Wilson, R.K., Gruber, T.A., Mullighan, C.G., Schlenk, R.F., Paschka, P., Döhner, K., Döhner, H., Bullinger, L., Zhang, J., Klco, J.M. and Downing, J.R.
Nature Genetics 48 (12): 1551-1556. December 2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis, F., Corbacioglu, A., Gaidzik, V.I., Paschka, P., Weber, D., Bullinger, L., Heuser, M., Ganser, A., Thol, F., Schlegelberger, B., Göhring, G., Köhne, C.H., Germing, U., Brossart, P., Horst, H.A., Haase, D., Götze, K., Ringhoffer, M., Fiedler, W., Nachbaur, D., Kindler, T., Held, G., Lübbert, M., Wattad, M., Salih, H.R., Krauter, J., Döhner, H., Schlenk, R.F. and Döhner, K.
Leukemia 30 (11): 2248-2250. November 2016

MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.
Shivarov, V., Dolnik, A., Lang, K.M., Krönke, J., Kuchenbauer, F., Paschka, P., Gaidzik, V.I., Döhner, H., Schlenk, R.F., Döhner, K. and Bullinger, L.
Haematologica 101 (11): e454-e456. November 2016

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik, V.I., Teleanu, V., Papaemmanuil, E., Weber, D., Paschka, P., Hahn, J., Wallrabenstein, T., Kolbinger, B., Köhne, C.H., Horst, H.A., Brossart, P., Held, G., Kündgen, A., Ringhoffer, M., Götze, K., Rummel, M., Gerstung, M., Campbell, P., Kraus, J.M., Kestler, H.A., Thol, F., Heuser, M., Schlegelberger, B., Ganser, A., Bullinger, L., Schlenk, R.F., Döhner, K. and Döhner, H.
Leukemia 30 (11): 2160-2168. November 2016

Integrating multiple molecular sources into a clinical risk prediction signature by extracting complementary information.
Hieke, S., Benner, A., Schlenl, R.F., Schumacher, M., Bullinger, L. and Binder, H.
BMC Bioinformatics 17 (1): 327. 30 August 2016

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.
Lueck, S.C., Russ, A.C., Botzenhardt, U., Schlenk, R.F., Zobel, K., Deshayes, K., Vucic, D., Döhner, H., Döhner, K., Fulda, S. and Bullinger, L.
Oncotarget 7 (31): 49539-49551. 2 August 2016

GPR56 contributes to the development of acute myeloid leukemia in mice.
Daria, D., Kirsten, N., Muranyi, A., Mulaw, M., Ihme, S., Kechter, A., Hollnagel, M., Bullinger, L., Döhner, K., Döhner, H., Feuring-Buske, M. and Buske, C.
Leukemia 30 (8): 1734-1741. August 2016

Genomic classification and prognosis in acute myeloid leukemia.
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., Potter, N.E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O'Meara, S., Raine, K., Jones, D.R., Teague, J.W., Butler, A.P., Greaves, M.F., Ganser, A., Döhner, K., Schlenk, R.F., Döhner, H. and Campbell, P.J.
New England Journal of Medicine 374 (23): 2209-2221. 12 July 2016

Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Rücker, F.G., Lang, K.M., Fütterer, M., Komarica, V., Schmid, M., Döhner, H., Schlenk, R.F., Döhner, K., Knudsen, S. and Bullinger, L.
Epigenetics 11 (7): 517-525. 2 July 2016

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
Li, S., Garrett-Bakelman, F.E., Chung, S.S., Sanders, M.A., Hricik, T., Rapaport, F., Patel, J., Dillon, R., Vijay, P., Brown, A.L., Perl, A.E., Cannon, J., Bullinger, L., Luger, S., Becker, M., Lewis, I.D., To, L.B., Delwel, R., Löwenberg, B., Döhner, H., Döhner, K., Guzman, M.L., Hassane, D.C., Roboz, G.J., Grimwade, D., Valk, P.J.M., D'Andrea, R.J., Carroll, M., Park, C.Y., Neuberg, D., Levine, R., Melnick, A.M. and Mason, C.E.
Nature Medicine 22 (7): 792-9. July 2016

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.
Bohl, S., von Harsdorf, S., Mulaw, M., Hofmann, S., Babiak, A., Maier, C.P., Schnell, J., Hütter-Krönke, L.M., Scholl, K., Wais, V., Schlenk, R.F., Bullinger, L., Ringhoffer, M., Döhner, H., Bunjes, D., Bommer, M. and Kuchenbauer, F.
Bone Marrow Transplantation 51 (7): 994-996. July 2016

GiANT: gene set uncertainty in enrichment analysis.
Schmid, F., Schmid, M., Müssel, C., Sträng, J.E., Buske, C., Bullinger, L., Kraus, J.M. and Kestler, H.A.
Bioinformatics 32 (12): 1891-1894. 15 June 2016

Low-grade glioma surgery in intraoperative magnetic resonance imaging: Results of a multicenter retrospective assessment of the German Study Group for Intraoperative Magnetic Resonance Imaging.
Coburger, J., Merkel, A., Scherer, M., Schwartz, F., Gessler, F., Roder, C., Pala, A., König, R., Bullinger, L., Nagel, G., Jungk, C., Bisdas, S., Nabavi, A., Ganslandt, O., Seifert, V., Tatagiba, M., Senft, C., Mehdorn, M., Unterberg, A.W., Rössler, K. and Wirtz, C.R.
Neurosurgery 78 (6): 775-86. June 2016

Identifying prognostic SNPs in clinical cohorts: complementing univariate ynalyses by resampling and multivariable modeling.
Hieke, S., Benner, A., Schlenk, R.F., Schumacher, M., Bullinger, L. and Binder, H.
PLoS ONE 11 (5): e0155226. May 2016

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Arreba-Tutusaus, P., Mack, T.S., Bullinger, L., Schnöder, T.M., Polanetzki, A., Weinert, S., Ballaschk, A., Wang, Z., Deshpande, A.J., Armstrong, S.A., Döhner, K., Fischer, T. and Heidel, F.H.
Leukemia 30 (5): 1220-1225. May 2016

Expression of a passenger miR-9* predicts favorable outcome in adults with acute myeloid leukemia less than 60 years of age.
Nowek, K., Sun, S.M., Dijkstra, M.K., Bullinger, L., Döhner, H., Erkeland, S.J., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (2): 303-9. February 2016

Aberrant expression of miR-9/9* in myeloid progenitors inhibits neutrophil differentiation by post-transcriptional regulation of ERG.
Nowek, K., Sun, S.M., Bullinger, L., Bindels, E.M.J., Exalto, C., Dijkstra, M.K., van Lom, K., Döhner, H., Erkeland, S.J., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 30 (1): 229-37. January 2016

2015

Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel, D., Schnaiter, A., Dodier, D., Jovanovic, M., Gerhardinger, A., Idler, I., Mertens, D., Bullinger, L., Stilgenbauer, S. and Fulda, S.
International Journal of Cancer 137 (12): 2959-2970. 15 December 2015

Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.
Schneider, V., Zhang, L., Rojewski, M., Fekete, N., Schrezenmeier, H., Erle, A., Bullinger, L., Hofmann, S., Götz, M., Döhner, K., Ihme, S., Döhner, H., Buske, C., Feuring-Buske, M. and Greiner, J.
International Journal of Cancer 137 (9): 2083-2092. 1 November 2015

Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana, K., Wang, J., Renneville, A., Bödör, C., Hills, R., Loveday, C., Savic, A., Van Delft, F.W., Treleaven, J., Georgiades, P., Uglow, E., Asou, N., Uike, N., Debeljak, M., Jazbec, J., Ancliff, P., Gale, R., Thomas, X., Mialou, V., Döhner, K., Bullinger, L., Mueller, B., Pabst, T., Stelljes, M., Schlegelberger, B., Wozniak, E., Iqbal, S., Okosun, J., Araf, S., Frank, A.K., Lauridsen, F.B., Porse, B., Nerlov, C., Owen, C., Dokal, I., Gribben, J., Smith, M., Preudhomme, C., Chelala, C., Cavenagh, J. and Fitzgibbon, J.
Blood 126 (10): 1214-1223. 3 September 2015

Immuntherapie von Kopf-Hals-Karzinomen - Highlights des ASCO-Kongresses 2015 [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
Laban, S., Doescher, J., Schuler, P.J., Bullinger, L., Brunner, C., Veit, J.A. and Hoffmann, T.K.
HNO 63 (9): 612-619. September 2015

Cellular origin of prognostic chromosomal aberrations in AML patients.
Mora-Jensen, H., Jendholm, J., Rapin, N., Andersen, M.K., Roug, A.S., Bagger, F.O., Bullinger, L., Winther, O., Borregaard, N., Porse, B.T. and Theilgaard-Mönch, K.
Leukemia 29 (8): 1785-9. August 2015

Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm, K.M., Langer, C., Monge, J., Bruins, L., Zhu, Y.X., Shi, C.X., Jedlowski, P., Egan, J.B., Ojha, J., Bullinger, L., Kull, M., Ahmann, G., Rasche, L., Knop, S., Fonseca, R., Einsele, H., Stewart, A.K. and Braggio, E.
Annals of Hematology 94 (7): 1205-1211. July 2015

Epo-induced erythroid maturation is dependent on Plcγ1 signaling.
Schnöder, T.M., Arreba-Tutusaus, P., Griehl, I., Bullinger, L., Buschbeck, M., Lane, S.W., Döhner, K., Plass, C., Lipka, D.B., Heidel, F.H. and Fischer, T.
Cell Death and Differentiation 22 (6): 974-985. June 2015

TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
Willer, A., Jakobsen, J.S., Ohlsson, E., Rapin, N., Waage, J., Billing, M., Bullinger, L., Karlsson, S. and Porse, B.T.
Leukemia 29 (5): 1018-1031. May 2015

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
Paschka, P., Schlenk, R.F., Gaidzik, V.I., Herzig, J.K., Aulitzky, T., Bullinger, L., Späth, D., Teleanu, V., Kündgen, A., Köhne, C.H., Brossart, P., Held, G., Horst, H.A., Ringhoffer, M., Götze, K., Nachbaur, D., Kindler, T., Heuser, M., Thol, F., Ganser, A., Döhner, H. and Döhner, K.
Haematologica 100 (3): 324-330. March 2015

Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.
Stolze, B., Reinhart, S., Bullinger, L., Fröhling, S. and Scholl, C.
Scientific Reports 5 : 8535. 23 February 2015

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm, K.M., Langer, C., Monge, J., Bruins, L., Egan, J.B., Zhu, Y.X., Shi, C.X., Jedlowski, P., Schmidt, J., Ojha, J., Bullinger, L., Liebisch, P., Kull, M., Champion, M.D., Van Wier, S., Ahmann, G., Rasche, L., Knop, S., Fonseca, R., Einsele, H., Stewart, A.K. and Braggio, E.
British Journal of Haematology 168 (4): 507-510. February 2015

2014

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Bruedigam, C., Bagger, F.O., Heidel, F.H., Paine Kuhn, C., Guignes, S., Song, A., Austin, R., Vu, T., Lee, E., Riyat, S., Moore, A.S., Lock, R.B., Bullinger, L., Hill, G.R., Armstrong, S.A., Williams, D.A. and Lane, S.W.
Cell Stem Cell 15 (6): 775-90. 4 December 2014

Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation.
Schlenk, R.F., Kayser, S., Bullinger, L., Kobbe, G., Casper, J., Ringhoffer, M., Held, G., Brossart, P., Lübbert, M., Salih, H.R., Kindler, T., Horst, H.A., Wulf, G., Nachbaur, D., Götze, K., Lamparter, A., Paschka, P., Gaidzik, V.I., Teleanu, V., Späth, D., Benner, A., Krauter, J., Ganser, A., Döhner, H. and Döhner, K.
Blood 124 (23): 3441-3449. 27 November 2014

A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples.
Risueño, A., Roson-Burgo, B., Dolnik, A., Hernandez-Rivas, J.M., Bullinger, L. and De Las Rivas, J.
BMC Genomics 15 : 879. 8 October 2014

New avenues for genetics guided therapeutic approaches in AML.
Bullinger, L.
Acta Haematologica Polonica 45 (4): 322-329. 1 October 2014

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype.
Feurstein, S., Rücker, F.G., Bullinger, L., Hofmann, W., Manukjan, G., Göhring, G., Lehmann, U., Heuser, M., Ganser, A., Döhner, K., Schlegelberger, B. and Steinemann, D.
BMC Genomics 15 : 784. 11 September 2014

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
Yun, H., Damm, F., Yap, D., Schwarzer, A., Chaturvedi, A., Jyotsana, N., Lübbert, M., Bullinger, L., Döhner, K., Geffers, R., Aparicio, S., Humphries, R.K., Ganser, A. and Heuser, M.
Haematologica 99 (9): 1456-1464. September 2014

The leukemogenicity of Hoxa9 depends on alternative splicing.
Stadler, C R, Vegi, N, Mulaw, M A, Edmaier, K E, Rawat, V P S, Dolnik, A, Bullinger, L., Heilmeier, B, Quintanilla-Fend, L, Spiekermann, K, Hiddemann, W, Döhner, K, Döhner, H, Feuring-Buske, M and Buske, C
Leukemia 28 (9): 1838-1843. September 2014

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.
Qu, Y., Lennartsson, A., Gaidzik, V.I., Deneberg, S., Karimi, M., Bengtzén, S., Höglund, M., Bullinger, L., Döhner, K. and Lehmann, S.
Epigenetics 9 (8): 1108-1119. August 2014

Expression profiling of leukemia patients: key lessons and future directions.
Shivarov, V. and Bullinger, L.
Experimental Hematology 42 (8): 651-60. August 2014

Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations.
Kühn, M.W.M., Bullinger, L., Gröschel, S., Krönke, J., Edelmann, J., Rücker, F.G., Eiwen, K., Paschka, P., Gaidzik, V.I., Holzmann, K., Schlenk, R.F., Döhner, H. and Döhner, K.
Haematologica 99 (8): 133-135. August 2014

Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.
Schneider, V., Zhang, L., Bullinger, L., Rojewski, M., Hofmann, S., Wiesneth, M., Schrezenmeier, H., Götz, M., Botzenhardt, U., Barth, T.F.E., Döhner, K., Döhner, H. and Greiner, J.
Leukemia 28 (8): 1759-62. August 2014

SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia.
Sasca, D., Hähnel, P.S., Szybinski, J., Khawaja, K., Kriege, O., Pante, S.V., Bullinger, L., Strand, S., Strand, D., Theobald, M. and Kindler, T.
Blood 124 (1): 121-133. 3 July 2014

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Döhner, K., Bühler, A., Böttcher, S., Ritgen, M., Kneba, M., Winkler, D., Tausch, E., Hoth, P., Edelmann, J., Mertens, D., Bullinger, L., Bergmann, M., Kless, S., Mack, S., Jäger, U., Patten, N., Wu, L., Wenger, M.K., Fingerle-Rowson, G., Lichter, P., Cazzola, M., Wendtner, C.M., Fink, A.M., Fischer, K., Busch, R., Hallek, M. and Döhner, H.
Blood 123 (21): 3247-3254. 22 May 2014

Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.
Hähnel, P.S., Enders, B., Sasca, D., Roos, W.P., Kaina, B., Bullinger, L., Theobald, M. and Kindler, T.
Blood 123 (15): 2355-2366. 10 April 2014

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar, B.G., Bullinger, L.B., McLean, K.M., Grauman, P.V., Harris, M.H., Stevenson, K., Neuberg, D.S., Sinha, A.U., Sallan, S.E., Silverman, L.B., Kung, A.L., Lo Nigro, L., Ebert, B.L. and Armstrong, S.A.
Nature Communications 5 : 3469. 24 March 2014

Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson, M.A., Gudgin, E.J., Horton, S.J., Giotopoulos, G., Meduri, E., Robson, S., Cannizzaro, E., Osaki, H., Wiese, M., Putwain, S., Fong, C.Y., Grove, C., Craig, J., Dittmann, A., Lugo, D., Jeffrey, P., Drewes, G., Lee, K., Bullinger, L., Prinjha, R.K., Kouzarides, T., Vassiliou, G.S. and Huntly, B.J.P.
Leukemia 28 (2): 311-320. February 2014

Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann, M.D., Lennerz, J.K., Bullinger, L., Bartholomae, S., Holzmann, K., Westhoff, M.A., Corbacioglu, S. and Debatin, K.M.
Experimental Hematology 42 (2): 90-100. February 2014

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.
Sonnet, M., Claus, R., Becker, N., Zucknick, M., Petersen, J., Lipka, D.B., Oakes, C.C., Andrulis, M., Lier, A., Milsom, M.D., Witte, T., Gu, L., Kim-Wanner, S.Z., Schirmacher, P., Wulfert, M., Gattermann, N., Lübbert, M., Rosenbauer, F., Rehli, M., Bullinger, L., Weichenhan, D. and Plass, C.
Genome Medicine 6 (4): 34. 2014

2013

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
Pellagatti, A., Benner, A., Mills, K.I., Cazzola, M., Giagounidis, A., Perry, J., Malcovati, L., Della Porta, M.G., Jädersten, M., Verma, A., McDonald, E.J., Killick, S., Hellström-Lindberg, E., Bullinger, L., Wainscoat, J.S. and Boultwood, J.
Journal of Clinical Oncology 31 (28): 3557-3564. 1 October 2013

The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients.
Piechnik, A., Dmoszynska, A., Omiotek, M., Mlak, R., Kowal, M., Stilgenbauer, S., Bullinger, L. and Giannopoulos, K.
International Journal of Cancer 133 (6): 1489-1496. 15 September 2013

CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
Astori, A., Fredly, H., Aloysius, T.A., Bullinger, L., Mansat-De Mas, V., de la Grange, P., Delhommeau, F., Hagen, K.M., Récher, C., Dusanter-Fourt, I., Knappskog, S., Lillehaug, J.R., Pendino, F. and Bruserud, Ø.
Oncotarget 4 (9): 1438-1448. September 2013

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
Schlenk, R.F., Taskesen, E., van Norden, Y., Krauter, J., Ganser, A., Bullinger, L., Gaidzik, V.I., Paschka, P., Corbacioglu, A., Göhring, G., Kündgen, A., Held, G., Götze, K., Vellenga, E., Kuball, J., Schanz, U., Passweg, J., Pabst, T., Maertens, J., Ossenkoppele, G.J., Delwel, R., Döhner, H., Cornelissen, J.J., Döhner, K. and Löwenberg, B.
Blood 122 (9): 1576-1582. 29 August 2013

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.
Dickson, G.J., Liberante, F.G., Kettyle, L.M., O'Hagan, K.A., Finnegan, D.P.J., Bullinger, L., Geerts, D., McMullin, M.F., Lappin, T.R.J., Mills, K.I. and Thompson, A.
Haematologica 98 (8): 1216-25. August 2013

Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke, J., Bullinger, L., Teleanu, V., Tschürtz, F., Gaidzik, V.I., Kühn, M.W.M., Rücker, F.G., Holzmann, K., Paschka, P., Kapp-Schwörer, S., Späth, D., Kindler, T., Schittenhelm, M., Krauter, J., Ganser, A., Göhring, G., Schlegelberger, B., Schlenk, R.F., Döhner, H. and Döhner, K.
Blood 122 (1): 100-108. 4 July 2013

Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik, V.I., Schlenk, R.F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H.G., Kremers, S., Greil, R., Raghavachar, A., Ringhoffer, M., Salih, H.R., Wattad, M., Kirchen, H.G., Runde, V., Heil, G., Petzer, A.L., Girschikofsky, M., Heuser, M., Kayser, S., Goehring, G., Teleanu, M.V., Schlegelberger, B., Ganser, A., Krauter, J., Bullinger, L., Döhner, H. and Döhner, K.
Blood 121 (23): 4769-77. 6 June 2013

Tailoring sparse multivariable regression techniques for prognostic single-nucleotide polymorphism signatures.
Binder, H., Benner, A., Bullinger, L. and Schumacher, M.
Statistics in Medicine 32 (10): 1778-91. 10 May 2013

PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17).
Bullinger, L., Schlenk, R.F., Götz, M., Botzenhardt, U., Hofmann, S., Russ, A.C., Babiak, A., Zhang, L., Schneider, V., Döhner, K., Schmitt, M., Döhner, H. and Greiner, J.
Clinical Cancer Research 19 (9): 2562-71. 1 May 2013

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
Krivtsov, A.V., Figueroa, M.E., Sinha, A.U., Stubbs, M.C., Feng, Z., Valk, P.J.M., Delwel, R., Döhner, K., Bullinger, L., Kung, A.L., Melnick, A.M. and Armstrong, S.A.
Leukemia 27 (4): 852-60. April 2013

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Paschka, P., Du, J., Schlenk, R.F., Gaidzik, V.I., Bullinger, L., Corbacioglu, A., Späth, D., Kayser, S., Schlegelberger, B., Krauter, J., Ganser, A., Köhne, C.H., Held, G., von Lilienfeld-Toal, M., Kirchen, H., Rummel, M., Götze, K., Horst, H.A., Ringhoffer, M., Lübbert, M., Wattad, M., Salih, H.R., Kündgen, A., Döhner, H. and Döhner, K.
Blood 121 (1): 170-7. 3 January 2013

CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.
Faber, K., Bullinger, L., Ragu, C., Garding, A., Mertens, D., Miller, C., Martin, D., Walcher, D., Döhner, K., Döhner, H., Claus, R., Plass, C., Sykes, S.M., Lane, S.W., Scholl, C. and Fröhling, S.
Journal of Clinical Investigation 123 (1): 299-314. 2 January 2013

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.
Fernández-Sáiz, V., Targosz, B.S., Lemeer, S., Eichner, R., Langer, C., Bullinger, L., Reiter, C., Slotta-Huspenina, J., Schroeder, S., Knorn, A.M., Kurutz, J., Peschel, C., Pagano, M., Kuster, B. and Bassermann, F.
Nature Cell Biology 15 (1): 72-81. January 2013

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Sun, S.M., Rockova, V., Bullinger, L., Dijkstra, M.K., Döhner, H., Löwenberg, B. and Jongen-Lavrencic, M.
Leukemia 27 (1): 100-6. January 2013